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The Co-operation Group to Combat Drug Abuse and Illicit Trafficking 
in Drugs (the Pompidou Group) is an inter-governmental body formed 
in 1971. Since 1980 it has carried out its activities within the framework 
of the Council of Europe’s Directorate General III – Social Cohesion. 
Thirty-five countries are now members of this European multidisci-
plinary forum in which policy makers, professionals and experts can 
exchange information and ideas on a whole range of drug misuse and 
trafficking problems. Its mission is to contribute to the development of 
multidisciplinary, innovative, effective and evidence-based drug poli-
cies in its member states. It seeks to link policy, practice and science. 
By setting up in 1982 its group of experts in the epidemiology of drug 
problems, the Pompidou Group was a precursor of the development of 
drug research and monitoring of drug problems in Europe. The multi-
city study – which aimed to assess, interpret and compare drug-use 
trends – is one of its major achievements. Other significant contribu-
tions include the piloting of a range of indicators (treatment-demand 
indicator) and methodological approaches such as a methodology for 
school surveys, which gave rise to the ESPAD (European School Survey 
Project on Alcohol and other Drugs).1 
The research platform has superseded the group of experts in epidemi-
ology active between 1982 and 2004. There has been a change of func-
tion from developing data collection and monitoring methodologies to 
assessing the impact of research on policy. This started with the 2004 
strategic conference on linking research, policy and practice – Lessons 
learned, challenges ahead – which identified as a major gap the lack of 
exchange of knowledge. 
The research platform’s prime role is to support better the use of 
research evidence in policy and practice, thus facilitating the devel-
opment of evidence-based policy. It also highlights the latest issues 
arising from social and biomedical drug research and promotes inter-
action between these disciplines and psychological drug research. 
Reports on these subjects are published regularly. An achievement is 
1. See Pompidou Group list of documents and publications at the end of this publication.
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the online register of current drug-research projects, set up in 2007 
in collaboration with the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) to improve the exchange of knowledge.
The present publication was commissioned by the Pompidou Group 
from Professor Richard Muscat, Chairperson, research platform 2007-
2010, and Professor Dike van de Mheen. It follows the original request 
from the Office Fédéral des Drogues et des Toxicomanies to acquire 
information on the ways in which drug policy is formulated and 
applied by other countries. This information provided the basis for 
the publication From a policy on illegal drugs to a policy on psycho-
active substances (Council of Europe, 2008), a retrospective analysis 
of drug policy in 17 member countries taking into account the social 
and cultural context. This analysis was aided by a synoptic reflection 
on the move from single policies on alcohol, tobacco and drugs to one 
which incorporates all these substances.
This publication is a further attempt to understand the scientific basis 
for choosing a separate policy for each substance or a single policy 
incorporating all substances and it also provides empirical informa-
tion on how such a choice today is put into practice. The seven coun-
tries considered here – Germany, Ireland, The Netherlands, Norway, 
Portugal, Switzerland and the United Kingdom – cover in turn the 
whole spectrum from the point of view of those opting for a single 
policy to one that incorporates all substances. 
The opinions expressed in this publication are those of the authors 
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1.  Theoretical overview
1.0.  Background
The result of the first attempt at examining the state of play in drug 
policy – looking at which countries have opted for a single drug policy 
and which seem to be moving in the direction of an all-encompassing 
policy that includes all psychoactive substances – prompted the next 
set of questions to be tackled. 
The publication that resulted, From a policy on illegal drugs to a policy 
on psychoactive substances, outlined the development of drug policy in 
each country, taking into account on a national level the ratification 
of any UN conventions, the adoption of EU drug strategies and any 
major changes that may have influenced the path taken by the country 
concerned and resulted in the situation in that country today.
The development of drug policy was framed in the context of each 
particular country – the size of the country, its geographical position 
and its relation to its neighbours, the state of the drug problem and 
public opinion – and supported by the political context, that is, the 
political ideology of the time and place.
This has resulted in descriptions of the development of drug policy 
in each country and how the evidence from science has generally not 
been taken into account, with the exception of epidemiology. This, as 
recorded, may be because some countries put drug policies in place 
some time ago and the science then was not what it is now, especially in 
relation to cognitive neuroscience, which has provided new vistas on the 
way we view brain and behaviour, and more notably mental health. 
The majority of the 17 countries opt for a separate policy for each 
psychoactive substance. The minority, those favouring an all- 
encompassing policy, were Switzerland, France, Ireland, Germany, 
Portugal, the Czech Republic and Norway. Norway appears to be the 
one country that has fully embraced integration; the United Kingdom 
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and the Netherlands seem steadfast in opting for separate policies on 
illegal drugs, tobacco and alcohol. 
On the basis of these findings, Germany, Ireland, the Netherlands, 
Norway, Portugal, Switzerland and the United Kingdom were selected 
to participate in the empirical study that follows, which in turn reflects 
the fact that the UK and Norway are at opposite ends of the scale, 
with the other countries on a continuum between these two countries. 
Consequently the study asked two questions:
–  What does the term “integrated policy” refer to in each of the 
seven countries?
–  How is “integrated policy” operationalised in the country?
This study of the seven countries follows the overview, which looks at 
theoretical rationales of opting for a single policy or one that includes 
all psychoactive substances. 
A key finding from the previous effort was that in all these countries 
the overarching policy consideration was health. For example, Norway 
makes it quite explicit why their policy includes both drugs and 
alcohol: it is because cognitive neuroscience has shown that all these 
substances affect the brain and behaviour and thus mental health 
status. The rationale for prevention is also made plain, being based 
on scientific findings that stopping early use prevents problems later 
on. In addition, harm-reduction measures – including substitution 
programmes and needle-exchange programmes – were introduced 
throughout Europe in response to the imminent health risks associ-
ated with injection drug use, which could have furthered the spread of 
HIV across Europe. Thus the threat to health of the citizens of Europe 
required policy responses that dealt directly with the problem. This 
latter example may have provided the foundations for a general move 
in the direction of basing drug policy on the health and well-being of 
the citizens in question. 
On a more general note, the EU seeks to look after the health, security 
and well-being of its member nations; the Council of Europe seeks 
not only to secure their health and well-being but also to uphold the 
human rights of its 47 member states. Public policy seems the obvious 
domain through which to achieve these aims, so drug policy per se or 
a policy for psychoactive substances can provide a tool to address the 
health and well-being of the nations in question, as part of a compre-
hensive health policy. 
A person’s well-being can be related to their physical, social and mental 
state. In essence, these factors provide the basis for a person to live life 
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to the full and therefore be a fully active member of society. Some 
basic needs have to be met, but this is what public policy is all about – 
ensuring that they are met – while putting the individual at the centre 
of any policy development. Monitoring health status provides one of 
the indicators of well-being, and this monitoring should include deter-
mining the use of tobacco, alcohol and drugs, all of which can have a 
detrimental effect on health and well-being (Johnston 2009, Wilkinson 
and Pickett 2009). Consequently, focusing on the mental and phys-
ical state of the individual addresses two of the three aspects directly 
related to well-being; and the third in a sense may also be taken into 
account in policy indirectly by adopting the Zinberg 1984 model, 
which addresses the social domain.
On the same line of thought, it is said that all these substances, 
tobacco, alcohol and illegal drugs, are more than just chemical agents 
which affect the brain and behaviour, and thus mental state; one must 
also consider the personality, attitudes, expectations and motivations 
of the user, as well as the context, because these have a significant 
influence on the user and the patterns of drug use. All these factors 
are determined by the complex wiring of the brain that in turn gives 
rise to these characteristics and is at the basis of why decisions are 
made to use or not to use such chemical agents and thus affect mental 
health. A scientific understanding of those brain systems that give 
rise to personality, or for that matter to motivation, is thus at the core 
of evidence-based policy development in this field, with the aim of 
assuring well-being through a healthy mind and body. The fact that 
treatment works is a further endorsement for a better understanding 
of the brain systems involved in mental health and well-being, and for 
the use of findings from neuroscience as a base for drug policy or a 
substance-misuse policy.
1.1.  Introduction
It is suggested that, in most domains, structure serves function or struc-
ture enables function. From a policy perspective having the appropriate 
ministries, departments and overall linking bodies provides the basis 
for policy implementation and monitoring. In the same way, the brain’s 
intricate wiring system allows communication between the circuits 
within particular structures and is the source of our behaviour. Thus 
again it would appear that structure serves function. This first part of 
the book deals with the theoretical perspective for a single policy or 
a policy that integrates all substances, thus providing the background 
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for policy formulation, and thus it has overarching consequences for 
the structure–function approach. 
Indeed the very term “integrated policy” conjures up different percep-
tions of what this could be. If one were only referring to an individual 
drug policy, then “integrated” would be understood to cover both supply 
of and demand for drugs. These then could be further broken down into 
their respective elements, namely from the supply standpoint, customs, 
police, the judiciary and the prison system; from the demand side, these 
elements could include prevention, treatment, harm reduction and 
social integration with an overall slant on research, evaluation and inter-
national collaboration. Thus from a single policy perspective, integration 
implies the inclusion of all necessary elements in a coherent manner.
If one were opting for a single policy for all psychoactive substances, 
then one’s perspective on the term “integration” would be slightly 
different; the attempt here would be to include all psychoactive 
substances in an appropriate manner. Thus “integrated policy” tends 
to take on different hues depending, in the first instance, on which 
policy option has been chosen.
Once such a decision has been taken, the term “integration” may then 
be applied to a second level, namely that of structure–function: that 
is, what structures are required to be in place before the policy can 
be implemented to provide the necessary outcomes. This has been 
addressed by the empirical study that follows, which gives some insight 
into how policies in this field have been implemented. It is discussed 
in Chapter 3, which also looks at the overall conclusions arising from 
both this overview and the empirical study.
The next question that arises is why bother with science in this policy 
domain? Epidemiology over the years has been the mainstay of most 
research done in the drugs field, and even more so in relation to 
alcohol. Thus from government, the main question has always been 
the size of the problem of use of psychoactive substances and their 
impact on society. Epidemiology has provided a means to estimate the 
size of the problem through population surveys, school surveys and 
snowball surveys, for example, that provide estimates of use over a life-
time, the past year and past month. These three, lifetime use, past-year 
use and past-month use, may be interpreted as trying the substance/s 
once, irregular use and regular use. Mathematical estimates may also 
be used to calculate numbers, for example of problem drug users that 
may need direct intervention and numbers in treatment, that show 
how well the said policy is having its desired effect. Finally, treatment 
outcomes may further support the policy in place. 
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Thus epidemiology has provided a means to determine the size of the 
problem. At the time of writing, the figures for drug use in Europe indi-
cate that about 23 million people have used cannabis in the past year 
(irregular use), some 4 million people have used cocaine, 2.6 million 
have used ecstasy and 2 million used amphetamine. Problem drug 
users or users of heroin and cocaine, the drugs that cause most harm 
and the most health and social costs, number about 2 million and 
there are approximately 7 500 fatal drug overdoses each year related 
to such problem drug use. There is also a high co-morbidity between 
drug use and mental disorders, both serious and more common. 
In the case of alcohol use, Europe remains the heaviest drinking region 
in the world with a yearly capita consumption of 11 litres of pure alcohol, 
which is double the world average. It is estimated some 55 million 
Europeans drink harmful levels of alcohol; of these 23 million are consid-
ered to be dependent. Such levels of harmful drinking are estimated to 
be responsible for some 195 000 deaths each year across Europe as a 
result of cancer, liver cirrhosis, neuropsychiatric conditions, suicides, 
road traffic and other accidents, and homicides (European Commission 
2009a). We may note that those road-traffic accidents where alcohol 
use is a contributing factor are predicted to rise to fifth place overall in 
the leading causes of death in 2030, from ninth in 2004 (1.3 million to 
2.4 million). The World Health Organization have announced that all 
193 member countries agree to confront the harmful use of alcohol by 
adopting a global strategy; its ten target areas include health services, 
community actions, pricing policies and reducing the health impact of 
illegal alcohol production (WHO 2010). 
Tobacco-related deaths worldwide in 2004 totalled 5.4 million and 
these are expected to rise to some 8.3 million by 2024, which would 
account for 10% of all deaths (WHO 2004). Tobacco use also contributes 
to cardiovascular disease, cerebrovascular disease, chronic obstructive 
pulmonary disease and some cancers. Moreover, the three leading 
causes of death worldwide in 2004 were ischaemic heart disease, cere-
brovascular disease and lower respiratory infections. 
Thus the prevalence of tobacco, alcohol and drug use in Europe is, 
to say the least, a problem that needs to be redressed because of the 
impact of these substances on mental and physical health and thus 
overall well-being.
As referred to above, use of these substances has an impact on our 
whole physiology and plays a major role in our health and well-
being, and thus our ability to live productive lives. Epidemiology 
has provided the means of estimating the global burden of disease, 
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but in addition it has extended the concept of the disability-adjusted 
life year (or DALY) to incorporate “potential years of life lost due to 
premature death to include equivalent years of ‘healthy’ life lost by 
virtue of being in states of poor health or disability” (WHO 2004). 
Biomedical research has now started to provide us with the ability 
to understand the mechanisms that give rise to use in the first place 
and the changes that result in a switch to dependence and the conse-
quences. Cognitive neuroscience is the field of research that is at the 
forefront of brain research tackling such issues. 
One caveat needs to be mentioned before we look at the brain 
systems thought to be at the centre of substance use. This is the fact 
that these psychoactive substances also have effects on other body 
organs; thus, for an integrated policy, these too should be taken into 
account. To some extent, as highlighted below, these effects will be 
considered, but not in all cases, so one should keep this mind when 
trawling through this text.
Psychoactive substances are so named because they primarily interact 
with the workings of the brain and thus alter behaviour. This implies 
that the brain is made up of a number of functional regions each 
specifically responsible for generating a particular aspect of our cogni-
tive abilities to enable us to make decisions and behave in the appro-
priate manner in the context we find ourselves. 
Which cognitive abilities do they affect? These types of substance 
seem to interfere with our ability to take decisions, make value judg-
ments and restrain our behaviour, and with our faculties of learning, 
memory, emotion and interoception. Hence, altering such func-
tions may result in pathological behaviour, which has become the 
typical diagnostic criterion used to determine dependence (American 
Psychiatric Association, Diagnostic and Statistical Manual of Mental 
Disorders, revd 2000; WHO 2003). These cognitive abilities also result 
from brain regions that sub-serve such functions; they include the 
frontal cortex (for decision making) and the hippocampus (for partic-
ular types of learning and memory). Moreover, the findings from scien-
tific literature that these cognitive abilities become compromised in 
patients with damage to such areas of the brain are further evidence 
of the role of these specific areas.
Before addressing each of these psychoactive substances in the next 
part of this overview, we need to examine briefly how these substances 
can affect brain function by interacting with neuronal communication. 
The brain is made up of some hundred billion cells – nerve cells – 
which in effect are the wires that make up the circuits within regions 
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of the brain and also connect all these regions in one way or another. 
Unlike the wiring in your house, which normally requires that an elec-
trical device be plugged into the mains to connect it to the supply of 
electricity, nerve cells are individual components – that is, they are not 
joined. But they need to pass electrical signals to one another and, to 
get around this problem, they make use of “chemical signalling”. An 
electrical signal is changed into a chemical signal to get it across the 
gap between the nerve cells and is then converted back to an electrical 
signal in the next cell.
The machinery of chemical transmission uses the lock-and-key concept: 
after the electrical signal arrives at the terminal, the nerve cell needs to 
produce and release the appropriate chemical; and the following cell 
needs to have in place the lock, the receptor, through which the key 
(the chemical) may open the gate. Understanding these mechanisms 
gives us the opportunity to come up with medicinal drugs that can 
correct aberrations in these processes, aberrations that have resulted 
in brain diseases ranging from depression to drug dependence itself. 
There are some one hundred brain chemicals, known as neurotrans-
mitters, that are released from nerve cells, and there are some hundred 
trillion connections operating on this principle. It is akin to having 
the wiring of the whole telephone network serving North and South 
America packed into some 1·2-1·3 kg of matter – that is what the brain 
weighs – mainly nerve cells, forming 2% of body weight.
1.2.  Scientific evidence
1.2.1.  Psychoactive substances
In the main, all psychoactive substances – that is, alcohol, tobacco 
and other drugs – interact with nerve cells to alter the way in which 
neuronal signalling takes place. More specifically, alcohol gets into 
most tissues or cells of the body as it is miscible in water and carried 
round the body in the bloodstream after it is absorbed following oral 
ingestion. The greater the blood supply to a particular organ, the 
greater the chances that alcohol gets into that organ – the brain, for 
example. Tissues, cells or organs that do not have such a good supply 
of blood take longer to absorb any alcohol through passive diffusion; 
however, when most of the alcohol has moved from the blood to parts 
of the body that have a rich supply of blood, then the reverse happens. 
Since alcohol in these tissues or cells is in a higher concentration than 
in the blood, some of it now moves back into the blood. 
16
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All in all, alcohol seems to get into most organs of the body, but it has 
specific effects on the nervous tissue found in the brain. Once in the 
brain, it interacts with nerve cells that release the inhibitory neuro-
transmitter gamma amino butyric acid (GABA for short) and these 
nerve cells’ corresponding receptors known as GABA A receptors; the 
effect is to prevent inhibition in some areas of the brain. Consequently, 
alcohol is thought to be a stimulant because it relieves some inhibition 
– for example, self-restraint – but in truth it is a depressant: further 
intake of alcohol disrupts speech, locomotor activity and fine co-ordi-
nated movements. Alcohol also elevates mood and interacts with the 
reward pathway by removing inhibitory inputs via the GABA system; 
thus one gets an elevation of the reward-signalling neurotransmitter 
dopamine, resulting in the feel-good factor as explained below. 
Alcohol also interacts with other neurotransmitter systems in the brain 
to modify their signalling. In particular, it is known to increase the 
release of opioid peptides that are involved with feelings of euphoria 
and pain relief (or analgesia). For this reason the opioid receptor-
blocker (or antagonist) naltrexone is used in treating alcohol abuse. 
This is a good example of how one may bolster the effect of one drug, 
such as heroin, by ingesting alcohol as well. Such drug interactions are 
common and may provide the basis for polydrug use in which the user 
gets to learn the effects of different drugs and combines them in the 
manner to ensure the “best effect” while perhaps ignoring detrimental 
effects – such as respiratory depression being amplified – when the 
two are combined. This may also arise when alcohol is combined with 
anti-anxiety medication such as diazepam; it is believed that alcohol 
inhibits the breakdown enzymes and thus increases the concentra-
tion of diazepam in the blood stream with the result once again of 
increased depression of respiration, which may result in total arrest.
Alcohol also results in vasodilatation of the peripheral blood vessels, 
causing the sensation of warmth and flushed skin, and is thus frequently 
used in cold weather. This may be dangerous because this feeling is 
due to the release of body heat for a short period and the inhibition 
of the reflexive, cold-induced vasoconstriction of the same peripheral 
vessels, so that now the person ends up colder than before. 
Chronic alcohol use has other effects on the peripheral system. Those 
of concern include cancer of the tongue, mouth, stomach and liver, as 
well as impotence in males and ovarian dysfunction in females. Fetal 
alcohol syndrome results in developmental problems in the unborn 




Nicotine is one of several compounds found in tobacco; it is a stimu-
lant, as is caffeine for example. The main reason why nicotine seems 
to produce dependence is the fact that, on inhaling a cigarette, within 
seven seconds 25% of the stimulant has already reached your brain 
– this is about twice as fast as when administered intravenously. In 
effect, the link between smoking and the feel-good factor is so nearly 
instantaneous that the habit easily becomes reinforced and this is the 
reason for its highly dependence-inducing nature.
Nicotine in the brain acts on what are termed nicotine receptors, 
though they would normally respond to the neurotransmitter acetyl-
choline. In general, nicotine acts on the reward system in which these 
receptors are present, receptors that give rise to the same euphoric 
feelings as those produced by other known stimulants such as cocaine 
and amphetamine. Although the mechanism through which these act 
is not the same, the overall outcome is the same – euphoria. Nicotine 
also has effects elsewhere throughout the nervous system in the rest 
of the body and thus is said to contribute to four of the five major 
causes of death highlighted above, including cardiovascular diseases, 
lung and other cancers, stroke and chronic obstructive pulmonary 
diseases. In 2010 it was reported that lung cancers in smokers harbour 
some 50 000 mutations or changes in their genetic material, compared 
to non-smokers (Lee et al. 2010).
The most-used psychoactive substance, other than alcohol and tobacco, 
is marihuana whose active naturally occurring cannabinoid is tetrahy-
drocannabinol, or THC for short. THC acts on the brain by interacting 
with cannabinoid receptors of which there are two types, CB1 and CB2. 
It is CB1 that is of main interest in that stimulation of this receptor leads 
to increased levels of dopamine in the reward pathway. Consequently, 
activation of these receptors again results in euphoria as well as altered 
sensations and memory impairment. Spice products that contain cannab-
inoids and the increase in THC concentrations obtained from the plant 
Cannabis sativa seem to be of major concern at present. 
The most notable stimulants are cocaine and amphetamine and both 
usually have a direct effect on the main neurotransmitter in the brain 
involved in generating feelings of euphoria. They act in turn by locking 
onto the dopamine transporter that is responsible for the uptake of 
dopamine back into the synaptic cleft after its release and interac-
tion with its receptors on the next neuron. In doing so they elevate 
the levels of dopamine to such an extent that some have described 
the feelings of euphoria that are produced following the ingestion of 
cocaine as greater than anything they have experienced. Both cocaine 
and amphetamine may induce visual and auditory hallucinations and 
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paranoia, symptoms typically attributed to schizophrenia. In the labo-
ratory, high-dose amphetamine administration has been used to model 
the symptoms of schizophrenia with the aim of trying to unravel what 
brain circuits may be responsible for that condition and what neuronal 
changes characterise the behaviour.
Cocaine also has effects on the peripheral nervous system and the 
organs that are innervated by what is known as the sympathetic 
nervous system. Thus, following ingestion of these stimulants, an 
increase in blood pressure occurs alongside an increased heart rate, 
heightened metabolic and respiration rates and elevated body temper-
ature, and all these seem to be a result of either the effects of these 
stimulants on nor-adrenaline uptake, which is similar to dopamine, 
or the direct effect of these agents on the brain centres that control 
sympathetic outflow.
Also included in this group of stimulants are the two members of the 
amphetamine family, MDMA (or ecstasy) and khat. At this juncture we 
focus on MDMA, which has been more popular than khat and mainly 
used at rave parties. Ecstasy acts mainly on the serotonin system to 
enhance release and inhibit the uptake of the said transmitter and 
this in turn results again in mild euphoria and a sense of well-being as 
well as increased sensory perception and a willingness to interact with 
others. Excessive use of ecstasy is said to result in a form of neurotox-
icity that results in damage to the serotonin neurons and thus a loss 
in their numbers as well as to some degree a form of memory impair-
ment. On a more acute level, ecstasy also increases the heart rate and 
blood pressure, elevates body temperature and increases sweating and 
salivation and it is these peripheral effects that put the individual in 
danger at rave parties where they are made worse by physical activity. 
Thus the “chill room” allows the user to stop dancing, cool down and 
take in the required water to replace that lost.
Last but not least, the opiates, such as morphine, interact with the 
opioid system in the brain, which is largely responsible for pain relief 
and the sense of well-being and euphoria. This class of compounds, 
in which heroin is a prime example, interact with opiate receptors of 
which there are three subtypes, mu, kappa and delta. Direct stimula-
tion of the mu receptor in the reward pathway of the brain by heroin 
is thought to be responsible for the feelings of euphoria it generates. 
Heroin seems to act by mimicking the effect of the endogenous opiate, 
enkephalin, and thus with repeated use the system shuts down the 
synthesis of enkephalin so that, on stopping use, the brain does not 
contain any significant amount of the said neurotransmitter which 
now results in dysphoria and heightened pain perception. 
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Methadone, another drug that mimics the effect of enkephalin but not 
so effectively, is used in heroin detoxification to reduce these major 
side effects but by decreasing the dose in a systematic way it gives a 
chance for the brain to restart the synthesis of enkephalin once again 
so that after three weeks the individual may be weaned off methadone 
altogether. A more recent medication used in the treatment of heroin 
addiction is buprenorphine, more frequently known as subutex. Once 
again this partial agonist has a maximal effect of around 65%, less than 
that of heroin but enough to enable the system to start functioning 
again in adverse circumstances.
This short résumé of the pharmacological and physiological effects 
of alcohol, tobacco and other drugs, all psychoactive substances, is 
intended as a prelude to the next section. (For more information, see 
Meyer and Quenzer 2005; Feldman, Meyer and Quenzer 1997.) 
1.2.2.  Reward system
A critical underlying mechanism that enables behaviour, especially 
goal-directed behaviour, is what is termed the reward system within the 
brain. This system, found just below the cortex, is thought to provide 
the mechanism that makes us likely to do things more frequently 
because these have resulted in rewards that make us feel good about 
what we have done. In simple terms, if eating, drinking and repro-
ducing did not make us feel good, none of us would be here today. 
More long-term goals – for example, obtaining a higher degree or 
indeed obtaining positive policy outcomes – require consistent behav-
iour over a period of time that finally results in the rewards such as a 
degree or re-election. So some rewards are obtained now (instant grati-
fication), others are obtained over an extended period of time (delayed 
gratification) and these alter our behaviour accordingly. Psychoactive 
substances seem to alter the reward pathway in a way that leads to 
instant gratification and not delayed gratification. 
The reward system in the brain is a circuit that arises from the midbrain 
and terminates in an area known as the ventral striatum. A number of 
neurons make up this circuit, releasing a variety of chemical agents 
to enable communication between them, but the principal neuro- 
transmitter that seems vital to providing some form of reward signal 
in this area is dopamine. It has been shown that stimulation of these 
nerves to release dopamine in this circuit is integral to providing the 
feel-good factor and that the behaviour leading to this is likely to 
be repeated in order to obtain this very outcome. In effect the final 
common pathway through which all psychoactive substances act, 
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even though they may not directly enhance dopamine release, is via 
increased release of dopamine in this reward pathway. Thus, on acute 
administration, or taking the substance the first time, the dopamine 
signal is enhanced in this pathway, with the result that the behaviour 
leading to this is reinforced with the likelihood that it is repeated. 
Some may argue that this in itself is not a bad thing, considering the 
sometimes mundane nature of life, but the risks that ensue include 
the development of addiction and dependence in which the sole form 
of reward is substance use because this provides greater pleasure than 
anything that is normally on offer such as that afforded by relation-
ships or the joy of watching a sunset by the sea in summer. In addition, 
for such a scenario to ensue, this does not happen overnight as changes 
in the brain occur gradually as a result of such use – but, more to the 
point, behaviour becomes altered as do certain cognitive abilities such 
as the ability to attend to stimuli and the ability to make what may be 
termed correct decisions in the prevailing circumstances.
The key point here is that psychoactive substances of all classes, be they 
alcohol, tobacco or drugs of abuse, hijack the brain-reward pathway 
by greatly amplifying the reward signal as provided by dopamine, 
which then results in the risk of further use that may lead to other 
consequences, such as poor decision making, that compromise behav-
iour. Repeated use over time leads to counteractive mechanisms in the 
brain coming into play, by which the impact of the reward signal is 
diminished and craving for the substance is increased. Consequently, 
other natural rewards are now less likely to activate the system and 
the likelihood of repeated use is further enhanced to keep the indi-
vidual from feelings of dysphoria or depression rather than euphoria 
following first use. 
The brain mechanism for this current scenario is thought to arise from 
the increase in dopamine signalling within the reward pathway; this 
comes into play by altering the firing pattern of the relevant neurons. 
In effect, the dopamine nerve cells operate under two conditions, tonic 
activity or phasic activity: the firing rate for these states is low for the 
former, some 2-5 times per second, whereas in the latter it may rise 
as high as 20 times per second. The implication of this is that the 
release of dopamine is low in the tonic state but high in the phasic 
state. All psychoactive substances have the property of shifting the 
bias of dopamine firing to the one known as phasic activity and thus to 
enhanced levels of dopamine when such substances are on board.
If this were all that occurred following the ingestion of such substances, 
one would expect all to revert to normal after use, but repeated use 
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continues to bias the system to phasic activity while the increasing 
propensity of the dopamine receptors to be less active is an attempt by 
the brain to counteract the effect of increasing levels of dopamine in 
the reward pathway. Thus, with prolonged use, the overall output of 
the system is turned down in that the increases in dopamine release 
are countered by the reduction in dopamine receptors. This is why it is 
thought that the user needs to keep using just to keep a “normal” level 
of functioning which otherwise would tip the other way, to dysphoria 
rather than euphoria, which is typical of what happens when the user 
stops using and more so in cases of withdrawal. 
Consequently, stopping use results in a stage that is characterised by 
the emergence of symptoms typical of depression and also anxiety and 
irritability. This state is stressful to say the least and thus the brain 
systems that give rise to these feelings come into play as a result of 
the alterations in the reward pathway that have impacted on these 
systems (for further information see Koob and Volkow 2010).
The underlying message would appear to be that psychoactive 
substances have a major impact on brain chemistry with an initial 
effect on the reward pathway that makes them so attractive. The brain 
is a dynamic organ and attempts to counteract the effects of these 
substances and thus the consequences of those effects. Learning takes 
place and memories are formed, which in turn affect the overall func-
tioning of the individual.
1.2.3.  Learning and memory
As hinted above, the repeated use of psychoactive substances starts to 
lead to a state where the impact of the reward is diminished and the 
wanting or craving for the substance increases. At first this is a conse-
quence of the reward threshold rising and thus the stimuli or cues 
associated with use are given greater prominence: the cues, usually 
the paraphernalia of use, become better linked with substance use 
and therefore are more noticeable to the individual now. Before people 
begin using a substance, these cues do not alert them or focus their 
attention. This increased salience of such cues is thought to be a prom-
inent aspect of craving and a means to guide behaviour to obtain the 
substance, to the detriment of other natural cues. 
This is akin to the feeling one gets when hungry, when one’s atten-
tion becomes alerted to visual presentations of food or just the smell 
of food; these cues take on more significance when one is hungry and 
guide one’s behaviour to obtain food to satisfy this need. Once food is 
consumed and the body has taken up the necessary nutrients, signals 
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are sent to the brain to alert it that this has happened, and the cues 
that had taken on extra significance when hungry lose their signifi-
cance till the next hunger pangs set in. Here we need to note two 
things: first, that we learn through conditioning what cues are associ-
ated with hunger that then successfully guide our behaviour to satisfy 
that specific need; and second, psychoactive substances seem to use 
the very same system of learning and cueing to guide us to the behav-
iour that obtains these substances, to the detriment of natural rewards 
like food and water.
The amygdala seems to be responsible for carrying information related 
to the various aspects of the cues used to guide behaviour. This struc-
ture is made up of a number of nuclei and it feeds into the reward 
pathway, so that the cues become better associated with the behav-
iour taking place. One can show that, after repeated pairings, the cues 
themselves will initiate the specific behaviour that prior to pairing 
they would not have done. In addition, in the laboratory, animals will 
continue to work or perform in the presence of these cues even if the 
reward, the psychoactive substance, is withheld. This again reinforces 
the view that these cues have a significant impact on behaviour. 
It has been argued that the mechanism responsible is sensitisation. By 
repeated association this strengthens the pathway linking cue-related 
information to reward-outcome information; thus the resulting aber-
rant learning and memory hold the key in guiding future behaviour.
There are several molecular mechanisms that have been suggested to 
account for learning and these in the main have been gleaned from 
work on another brain structure involved in learning and memory 
related to context or the spatial domain – the “where”. The hippo- 
campus is thought to be the brain structure that provides for episodic 
memory or, more colloquially, the ability to recall personal experiences 
that depend on the “what”, “where” and “when” (see Dickerson and 
Eichenbaum 2010). Information about where is encoded in the hippo-
campus and this is also sent to the reward pathway, so now the whole 
picture can be put in perspective, namely taking in the substance in 
question in its defined context together with inputs of the particular 
cues (amgydala input) that accompanied the rewarded behaviour. 
Thus, places where the substance has been used, as with the cues 
mentioned above, may take on greater significance for the user and 
provide the same urge to use the same substance when in the same 
contexts or places. Thus memories of places or episodes associated 
with substance use may in turn bias behaviour or decision making to 
further use. This again may be the setting shown by the Zinberg 1984 
model referred to above (see also Chapter 2).
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Thus the question of why does the use of all psychoactive substances 
have such an impact on future behaviour may be answered to some 
degree by the apparent aberrant learning and memories that are stored 
after such use, which then have a great impact on guiding future behav-
iour. Moreover, the mechanism thought to give rise to such memories 
in the hippocampus and other parts of the brain, such as the reward 
pathway, is related to what is known as long-term potentiation (or LTP 
for short) in which neuronal connections are strengthened, making 
them more likely to contribute to neuronal activity in the future and 
thus guide behaviour.
1.2.4.  Decision making
The ability to make the correct choice under the prevailing circum-
stances is what drives behaviour forward. Information reaches the 
frontal cortex, the site at which decisions are made, from the reward 
pathway through the thalamus, which appears to be the main gateway 
through which most stimuli gain access to this higher structure. It is 
worth noting that, from an evolutionary perspective, the cortex has 
evolved more than any other other brain structure. 
Information from sub-cortical sites such as the striatum, amygdala 
and hippocampus may also flow directly into the cortex; as well as 
activating the reward pathway, this information may at the same time 
activate the cortex. Thus, coincident activation takes place of all the 
structures in question, which biases decision making by the frontal 
cortex in support of those behaviours that to one degree or another 
provide the best outcome in the specific context. Thus the goal of any 
substance user is to feel very good and now behaviours that support 
such an outcome are given prominence, irrespective of the negative 
consequences if they do exist.
In a number of studies that explicitly examined this phenomenon – 
studying, for example, the choice between an instant small reward and 
a larger one that is delayed in time – most people on any substance 
opt for the small instantaneous reward. In some studies this has been 
taken a step further, to determine whether the person will work to 
obtain a reward that is also linked to a negative outcome, the outcome 
being that they will still work for such a reward. Consequently, the use 
of psychoactive substances biases the decision-making process of the 
frontal cortex even if the outcome is also partly negative, as long as the 
final result is achieved – namely, obtaining the substance.
It is interesting that substance users, when making decisions, appear 
to behave in ways very similar to patients who have a damaged frontal 
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cortex for one reason or another: they make choices that bring instant 
reward at the risk of incurring loss of reputation, job, home and family 
(Rogers et al. 1999). Moreover, impulsive behaviour – which again 
seems to stem from a problem with the circuitry in the frontal cortex 
– is a major risk factor for the use of psychoactive substances and espe-
cially for substance dependence (but see below).
A conceptual framework has been formulated to understand how 
information reaching the cortex via other brain structures guides 
behaviour and thus choice. This suggests that the reward pathway is 
responsible for converting incoming sensory signals to some common 
“reward currency” that is in turn transformed by the cortex with 
the help of the reward system into a value presentation of the said 
stimuli. This value is then mapped onto the probability of available 
choices of behaviour. Psychoactive substances may bias this process 
so that stimuli related to use are given more value in reward currency 
than other, more natural stimuli. It is akin to money markets, where 
it is often perceptions of the strength of a particular currency that 
cause more people to invest in that currency than others with less 
perceived value.
Once a decision has been made to act, the required motor programmes 
in the brain need to be enabled in order to execute the intended 
actions. Here again the motor cortex communicates with a sub-cortical 
structure, namely the dorsal striatum, which is thought to be primarily 
responsible for influencing the motor cortex in selecting the appro-
priate actions. A current theory for addiction/dependence invokes the 
dorsal striatum, primarily because of its role in maintaining habits – be 
they good or bad. In a state of dependence, information processing in 
this structure is biased to favour selection of those actions that lead 
to obtaining the substance of interest (Everitt et al. 2008). Compulsive 
behaviour also involves the dorsal striatum and thus it is suggested 
that use in the first instance may kicked off by a predisposition to be 
impulsive, as this is one of the risk factors, but then later on repeated 
use is supported by the formation of habit, which in turn becomes 
compulsive (see section 1.2.5 below).
1.2.5.  Addiction/dependence
First and foremost, the epidemiological evidence to date suggests that 
not all people who try a psychoactive substance become addicted to 
it. Moreover, it has been estimated that – of those who try such a 
substance once – the chances that addiction/dependence will set in 
are 1 in 10 for marihuana and 1 in 3 for tobacco, with other substances 
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falling in between. Thus the tendency to become addicted/dependent 
should not be the only measure of the impact of these substances on 
bodily health, as outlined above, but the problem of addiction/depend-
ence is still there for all to see and needs redress.
Based on our current understanding it would appear that there is 
some molecular switch within the system that turns occasional drug 
use into uncontrolled compulsive drug use with the known conse-
quences. A protein molecule known as Delta Fos B has been identified 
as the molecule that may provide this switch, because quantities of 
this protein increase following the intake of any type of drug of abuse. 
More importantly it is activated following repeated use and thus the 
response does not adapt or habituate; hence it may be this molecule 
that enables the transition to long-term sensitisation of the striatal 
dopamine function that is said to be responsible for people craving 
or wanting a substance. This particular protein is synthesised from 
the activation of what is known as an immediate early gene, the c-fos 
gene, following drug stimulation and in turn the product of this gene, 
Delta Fos B, may switch on or off conventional genes that may be 
responsible for the long-term effects associated with chronic drug use 
(Nestler 2008). 
Repeated use results in tolerance to the rewarding or pleasurable 
effects that these substances produce. To overcome the effect of toler-
ance, further drug use ensues in an attempt to obtain the original 
effect. Thus with repeated drug use the reward threshold is increased 
and not decreased, and on stopping use the individual goes into a 
state of dysphoria rather than euphoria as a result of the tolerance or 
down regulation of the dopamine receptors within the reward circuit. 
Consequently stimuli with greater impact are required to activate the 
reward system. To offset this condition the user would seek to obtain 
and take in more drugs, setting up a sequence of events that gives rise 
to compulsive drug use (Koob and Le Moal 2008).
Among the consequences of repeated drug use are dependence/addic-
tion and strengthening of the circuits in the brain involved in habit 
formation. Thus compulsive drug use, like addiction, arises from a 
series of steps or conditions that alter what is known as the striatal 
circuitry to give rise to the aberrant behaviour observed in the clinic. 
However, initiation of drug use is under the control of the ventral 
striatum, most notably the nucleus accumbens core region that proc-
esses information related to motivation/reward. With repeated use of 
the drug over a long period, the maintenance of or switch to drug 
dependence/addiction occurs as the dorsal striatum takes over. This is 
primarily involved in the selection of action as pointed out above. 
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Impulsivity also increases the likelihood of addiction and relapse. In 
subjects selected for impulsivity, findings from the laboratory show that 
they learn to administer cocaine in the same way as the control group, but 
they then take on board more and more of the drug than their counter-
parts. It has also been shown that they have low D2 receptor availability 
in the ventral striatum, as do human drug addicts (Volkow et al. 2004) 
and also when abstinent (Volkow and Wise 2005). Thus impulsivity per 
se may predispose one to use drugs in the first place and then facilitate 
the switch between occasional use and drug dependence/addiction, and 
finally also render abstinent addicts more susceptible to relapse. 
Thus our current understanding from science indicates that addiction/
dependence only sets in with individuals who repeatedly use these 
substances. There may be a molecular switch that is flipped at a certain 
point in time and instantiates the decreased sensitivity to rewards and 
increased craving with the accompanying behaviour changing from 
impulsive to compulsive.
1.2.6.  Psychiatric disorders
It has been suggested that impulse-control disorders resemble addic-
tions; some writers have even gone as far as stating that these disorders 
may be considered addictions (Brewer and Potenza 2008). Impulse-
control disorders are said to fall along a continuum in the impul-
sive–compulsive domain. They include pathological gambling and 
kleptomania, and are usually repetitive and pleasurable. Impulsivity 
per se may be a key factor in some psychiatric disorders, including 
impulse-control disorders and addiction/dependence. The characteris-
tics of impulsivity include lack of premeditation and sensation-seeking, 
but key to its resemblance to dependence/addiction is the definition 
given by Moeller et al. (2001): “a predisposition to rapid unplanned 
reactions … with diminished regard to negative consequences”. 
From a genetic standpoint it is uncanny that family and twin studies 
account for up to 60% of the variance for risk of dependence/addiction 
(Kreek et al. 2005). In relation to specific factors in human and animal 
studies, it appears that the reduction in availability in dopamine D2 
receptors is a possible basis for a mechanism for both impulsiveness 
and the development of addiction/dependence. 
The presence of substance dependence is also associated with affec-
tive disorders, anxiety disorders, attention-deficit disorder and person-
ality disorders and it is more likely to abound in this cohort than in 
the general population. Major depression, anxiety and personality 
disorders are thus found more commonly among those with substance 
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dependence than in the population at large (Couwenbergh et al. 2006; 
Ross et al. 1988; Merikangas et al. 1998).
In addition, those diagnosed with substance dependence are more 
at risk than the general population of developing a related addictive 
disorder at some point in their lifetime. Moreover, their first-degree 
relatives are also at greater risk than the general population of devel-
oping an addictive disorder, which includes substance dependence.
Which comes first, the psychiatric disorder or substance dependence? 
It has been demonstrated that disorder predates dependence by typi-
cally five to ten years (Couwenbergh et al. 2006; Shaffer and Eber 
2002). It has also been reported that there are significant predictive 
associations between primary mental disorders, first substance use 
and dependence among problem drug users. However, in practice it 
appears that anxiety disorders – and, to a lesser extent, depression – 
precede and increase the risk for substance use. We may thus infer 
that substance dependence does not arise as result of the lifestyle that 
may be attributed to the syndrome but from some underlying neuro-
biological dysfunction.
1.2.7.  Genetic predisposition
It is now understood that dependence/addiction – or the vulnerability 
to developing this disorder – is influenced by the type of genes we 
inherit from our parents. That is not to say that the social context 
does not have a say in the development of dependence/addiction but 
genetic heritability is some 50% independent of the substance in ques-
tion. It may be higher for specific substances: for heroin, it is reported 
to be in the region of 70%. 
Recent studies in this field have suggested that dependence/addic-
tion is heterogenous from a genetic standpoint, as well as polygenic. 
This implies that in the first instance a set number of genes acting 
independently may together produce vulnerability to dependence, 
but that seems to provide only a small propensity to develop depend-
ence and polygenicity appears to be the main factor. Polygenicity in 
this case means a number of genes acting in concert to produce the 
vulnerability, with no single gene responsible. In the light of these 
findings, it has been proposed that it may prove to be more fruitful 
to examine the genetic influence on a particular feature or trait 
that has a corresponding biological substrate and thus be able to 
account for the single genes responsible (see below). This has proved 
to be challenging except for example in the case of some particular 
sub-typing with respect to alcohol. Accordingly, this sub-typing of 
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alcohol dependence has produced a more homogenous grouping and 
thus reduced the overall number of characteristics that may be attrib-
uted to this disorder (Wong and Schumann 2008). 
1.2.8.  Psychological traits
There appear to be five personality traits. One of them is extraver-
sion, which includes the more specific trait impulsiveness, and that 
seems to increase the risk for developing substance dependence. 
Specific traits within the extraversion grouping – impulsiveness, 
sensation-seeking, risk-taking, low stress tolerance and nonconformity 
– normally predate the use of psychoactive substances. It has been 
suggested that such traits are heritable and that normally genes and 
environment contribute equally to the development of any such trait, 
which is rather stable throughout life. Thus it would appear that the 
trait of impulsiveness, which in effect is non-pathological (which is not 
the case in psychiatric conditions), is a risk factor for the initiation of 
substance use.
Impulsiveness, it is argued, may also be divided into a number of sub-
traits, such as urgency, lack of perseverance, lack of premeditation and 
sensation-seeking (Lynam et al. 2006). The dimension of urgency – 
that is, negative urgency, the tendency to give in to strong impulses 
specifically when accompanied by negative emotions, which may take 
the form of anger, anxiety or depression – was found to be the main 
factor in a group of substance dependants. Sensation-seeking is also 
related to initiation of substance use; it can be described as the need 
for novelty or seeking activities that provide intense stimulus, such as 
skydiving. Research using constructs that are able to measure this trait 
has shown over the years, in studies of alcohol users, that sensation-
seeking is correlated with greater quantity and frequency of alcohol 
use. In addition, in the laboratory it has been shown that exposing the 
young to alcohol or cocaine enhances novelty-seeking and thus it has 
been argued that novelty-seeking per se may cause people to further 
engage in substance use.
The trait of impulsiveness, like other personality traits, is also consid-
ered to be influenced by both biological and environmental determi-
nants. It may be that, in individuals who tend to be impulsive, it is 
the lack of impact from normal rewarding stimuli – a lack of impact 
that may be caused by a down regulation of their dopamine receptors 
within the reward pathway – that leads them to seek more intense 
stimuli to get their reward system up and running as required. It has 
also been proposed that it is some alteration to the frontal cortex 
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circuitry that enables impulsiveness, because results from people with 
lesions to this area show that, in choice tests where the subject may 
either take a small reward with no delay or a large reward following a 
delay, the small reward is always chosen.
1.2.9.  Sociological determinants
Each of the big five personality traits is made up of what may be called 
sub-traits, and they all include an element of what it is to interact with 
our environment, especially with other people. This notion of interac-
tivity, or more specifically the ability to co-operate with others, is at the 
essence of what it is to be human. The way in which the environment 
and the individual interact then provides the basis for the building 
of family units (whatever the definition of these), communities and 
society at large. Thus the environment or culture per se may impact on 
societies and the individual participating in them. 
To be able to behave in this way, a scientist would argue, one must 
“have a theory of mind” to be able to read other people’s minds or 
mental states, because these mental states determine behaviour. Mental 
states vary in type and form from the long-term to the short-term – 
for instance, trustworthiness as opposed to flippancy or, in the short 
term, anger versus happiness. There are also desires, which can take 
one form or the other and are usually goal-directed, and beliefs, which 
govern our behaviour even though they may be false. The point is that 
these “mental states” – both our own and those of others – are strictly 
speaking not physical phenomena, though they very much depend on 
the neuronal workings of the brain.
To this end the brain structures that help instantiate the ability to have 
theory of mind include the frontal cortex, the limbic system (involved 
in reward processing) and the superior temporal sulcus. The limbic 
system provides information on emotional content, enabling us to 
read people’s emotions and helping us to empathise with loss or share 
in the glory of one’s football team winning the world cup. Without 
this ability to read people’s emotions, society would be in a bad state, 
unable to recognise such signals, just as computing in the field of 
Artificial Intelligence has not been able to do so far. 
The underlying mechanism that enables theory of mind within this 
circuitry in the brain is thought to be based on what may be termed 
“mirror neurons” that are activated by our own ability to express 
emotions; but crucially these mirror neurons are also activated when 
other people express their emotions. Using this basic mechanism, it is 
thought, we can experience the same emotion as that expressed by the 
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other person, even though at that instant we may not know the basis 
for their feelings. The inference is that the mirror system is best placed 
to track changes in mental states, such as emotional states and inten-
tions of others, that per se may lead to alterations in behaviour. 
Because this ability to attribute mental states to self and others is seen 
as an important determinate of behaviour, it is hardly surprising to 
learn that problems in this circuitry in the brain lead to problems in 
interacting with others. On the extreme end of the scale, autism is a 
condition where theory of mind has been disabled and it has been 
suggested that the mirror-neuron system is to blame in part for the 
emergence of the symptoms of this disorder. Autism is an example of 
the emergence of problems as a consequence of developmental prob-
lems, whereas disorders like schizophrenia that develop later on in 
life are said to result in problems in applying theory of mind to form 
coherent relations with others and the world. The long-term use of 
psychoactive substances may result in symptoms comparable with 
those associated with schizophrenia, as sometimes noted with amphet-
amines and cocaine, which in turn may result in loss of the ability to 
attribute mental states to oneself and in some cases to others. The 
mechanism for such a loss is believed to arise from a dysfunctional 
inhibitory pathway from the cortex to the sub-cortical structures 
forming part of the limbic circuit, which is responsible for processing 
information related to emotions.
Personality traits may be one of the risk factors for starting to use 
a psychoactive substance, apart from the well-known phenomenon 
of peer pressure. Among these traits are expectancy, a well-known 
psychological construct that includes the belief that the benefits of use 
outweigh the risks, and finally the belief that one is in control of one’s 
use. So all in all, sociological determinants are very much influenced by 
the underlying brain system through which choices are made, but in 
truth a decision to initiate substance use in the first place depends on 
the workings of the individual mind, as does (in a number of people) 
the switch to dependence.
1.3.  Discussion
The foregoing overview of the impact of psychoactive substances on 
the brain and behaviour has attempted to show that the evidence from 
science has come a long way. This in turn should raise our under-
standing of why people use such substances in the first place and why 
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some users unfortunately go on to become addicted/dependent with 
the resultant problems.
It would appear that the crux of the issue is the finding that these 
substances have a major impact on the reward pathway, such that the 
mental states or feelings of euphoria they generate continue to attract 
a fair number of individuals to experiment with these substances. It is 
also worth noting that the majority of users seem to be in the younger 
age groups, starting at 16 years old, and this is a problem in itself 
because the frontal cortex – the part of brain mainly responsible for 
decision making – only fully matures at the age of 20. 
It is understood that our mental states – one of them being our beliefs – 
in turn determine our actions or behaviour. Beliefs are synthesised in our 
minds by the assumption that knowledge depends on experience; thus, 
for example, in order to obtain happiness (a short-term mental state) the 
path one takes may involve the use of psychoactive substances to create 
this false belief. It is possible that our make-up or psychological traits 
may predispose some of us more than others to try such substances, and 
this is starting to be borne out by the findings that our genes give rise 
to our psychological traits, whatever they are. It needs to be emphasised 
that not all is clear-cut and the big five psychological factors are broad 
categories and thus not as good at predicting or explaining behaviour as 
are the sub-types or lower-level traits. 
Of all the traits, impulsiveness seems to be the one that provides most 
risk for substance use in the first place and risk of dependence there-
after and this trait falls under the larger domain of extroversion. That 
impulsiveness per se may be in part understood to arise from the 
reward circuitry in the limbic system being down regulated by the 
lack or insensitivity of D2 receptors demonstrates that neuroscience 
is beginning to provide us with new insights into how such brain 
circuitries may instantiate such behaviour. Again, the issue needs to 
be viewed in its total context in that correcting such behaviour with 
medication alone is not the whole answer. Recent cognitive findings, 
in which memories have been altered, provide a way forward in which 
both medication and cognitive therapy may bear better outcomes. 
One last note: the emerging discipline of social cognitive neuroscience 
– which merges such disparate fields of study as sociology at one end, 
neuroscience at the other and cognitive psychology in between – has 
been described by Ochsner and Lieberman as seeking to 
to understand phenomena in terms of interaction between three 
levels of analysis: the social level, which is concerned with the 
motivational factors and social factors that influence behaviour 
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and experience; the cognitive level, which is concerned with the 
information processing mechanisms that give rise to social-level 
phenomena; and the neural level which is concerned with the brain 
mechanisms that instantiate the cognitive level processes. 
1.4.  Conclusion
Following the first attempt to understand in descriptive terms what led 
to the development of policies on alcohol, tobacco and other drugs, 
it was clear that epidemiology was the main consideration, not social 
cognitive neuroscience. It appears that this now needs to be redressed 
irrespective of whether a single policy or an integrated policy for all is 
the choice.
The main issue raised in sections 1.0 and 1.1 above was health and 
well-being. It was stated that most institutions aim to have policies 
that provide for the health and well-being of their citizens. In addi-
tion, the social domain was taken into account as the third pillar 
that public policy seeks to address. Public policy is also relevant here 
because it supplies the over-arching umbrella under which such items 
as alcohol, tobacco and drug use may shelter. The findings of the first 
study pointed to health as a major consideration in deciding what type 
of policy to have on the use of psychoactive substances. It is also clear 
here that measures of health, well-being and the global burden of 
disease – measuring, for example, lost days due to ill health or prema-
ture deaths – have been an important advance in evaluating how well 
policy has been implemented. The most recent findings from social 
cognitive neuroscience provide insights into what determines our 
health and well-being – in either the absence or presence of psychoac-
tive substances – and as such should be taken on board in developing 
and implementing policy in this domain.
Policy-makers looking to ensure health and well-being might also 
want to consider what elements could constitute a healthy lifestyle 
and promulgate these to the whole population, but most importantly 
to those who are at most risk of developing practices that are unhealthy 
or may jeopardise health and well-being in the future. Secondary 
prevention may be used as a tool, for example in campaigns targeting 
youngsters with specific psychological traits like sensation-seeking 
that guide their decisions. It is also acknowledged that preventing use 
when young reduces problems related to use later on. 
Policies related to health and well-being also need to include the 
latest findings from science when attempting to address those who 
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have become addicted/dependent with repeated use. Harm-reduction 
policies came into being as a result of the need to tackle emerging 
health problems, mainly those related to the spread of HIV. In general, 
national policies followed only after measures on the ground proved 
positive, but in future this pattern needs to be reversed because policy 
makers should take cognisance of current scientific evidence earlier 
on. Treatments in this field are advancing at a considerable pace: at the 
time of writing, a cocaine vaccine will be available within the year and 
a nicotine vaccine shortly thereafter.
Whether we opt for a policy for each substance or an integrated one 
for all now seems to need further consideration in the light of scientific 
findings and what actually happens in practice. The second part of this 
book attempts to understand the current state of play by an empirical 
analysis of practice and the reasons for it.
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2.  Empirical study of integrated drug policy
2.1.  Introduction
The term “integration” or “integrated” may refer to a range of domains 
in which parts that were separated become one.2 When it is used to 
characterise drug policy, the term “integrated” is often used in different 
ways. The EU Drugs Strategy, 2005-2012 (Council of EU 2004, p. 2) aims 
“to offer a high level of security for the general public and to take a 
balanced, integrated approach to the drugs problem”. It uses the terms 
“balanced” and “integrated” according to the “UN General Assembly 
Special Session on Drugs of 1998 which confirmed the importance of 
the integrated and balanced approach, in which supply reduction and 
demand reduction are mutually reinforcing elements in drugs policy” 
(ibid.). So, in the EU drugs strategy, “integrated” refers to a drugs policy 
that focuses on reduction of both supply and demand. 
The term “integrated” in this EU document does not refer to a compre-
hensive view on addiction or problematic substance use that includes 
legal substances, illegal substances and compulsive behaviour that is 
not substance-related (gambling, gaming). The EU drugs strategy is 
entirely dedicated to illegal substances. 
The EU Strategy to Support Member States in Reducing Alcohol-related 
Harm (European Commission 2006) focuses uniquely on alcohol; 
tobacco and illegal psychoactive substances are not mentioned once. 
The document addresses the health, social and economic issues of 
hazardous alcohol consumption and encourages member states to 
co-ordinate national actions on five alcohol-related themes.3 These 
2. Wikipedia (en) lists various forms of integration; see http://en.wikipedia.org/wiki/ 
Integration (retrieved 25 February 2010).
3. The five themes are: 1. Protect young people, children and the unborn child; 
2. Reduce injuries and death from alcohol-related road accidents; 3. Prevent alcohol-
related harm among adults and reduce the negative impact on the workplace; 4. Inform, 
educate and raise awareness on the impact of harmful and hazardous alcohol consump-
tion, and on appropriate consumption patterns; 5. Develop and maintain a common 
evidence base at EU level.
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themes “call for multi-stakeholder and multi-sector action” (p. 7). This 
phrase refers to integrating the co-ordination of local and national 
actions. 
In the EU white paper Together for Health: A Strategic Approach for the 
EU 2008-2013 (European Commission 2007) one of the fundamental 
principles is that health policy should be integrated into all other 
policies. It is called the HIAP (Health In All Policies) approach. HIAP 
refers to both horizontal and vertical integration. Horizontal integra-
tion means the integration of policy domains (economy, environment). 
Integration of political levels (EU, national, regional) could be viewed 
as vertical integration. In this study we have made no distinction 
between horizontal and vertical co-ordination.
In a paper of the research platform of the Pompidou Group, Muscat 
(2008) defines integrated policy as a policy on all psychoactive 
substances rather than a single policy for each substance. Muscat iden-
tifies Switzerland, France and Norway as countries that opt for one 
policy on all substances, and the UK and the Netherlands as coun-
tries with a clear single-substance policy. When discussing this paper, 
members of the research platform observed a lack of theoretical consid-
erations with respect to integrated policy – other views on integrated 
policy could be relevant as well – and they wondered whether an 
“integrated policy” takes into account the interaction between policy 
measures. For example: public security issues that emerge as an effect 
of the tobacco ban in bars and restaurants, or the ban on the precursor 
PMK used to produce MDMA, may propel the introduction of other 
substances, such as mephedrone. Another related question could be: 
is an integrated policy (regardless of the aspects that are integrated) 
a better tool than single-substance policies to attain the overarching 
objective of all European drugs policies, namely protecting society and 
improving health (Muscat 2008)?4 These ‘new’ questions are dealt with 
later in this chapter.
It is obvious that the legal status of psychoactive substances may 
have consequences for the individual and society, but this book does 
not address legal issues. Here we look at integrated substance poli-
cies from a public health perspective, in line with the WHO view that 
public health is “a social and political concept aimed at improving 
health, prolonging life and improving the quality of life among whole 
populations through health promotion, disease prevention and other 
4. Interestingly, the EU Drugs Action Plan (mentioned above) juxtaposes “security” and 
“health” as equally important aspects of “illicit drugs”. Apparently, at EU level, there is 
more to illegal drugs than just health issues.
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forms of health intervention”.5 It can be observed that, regardless of the 
status of a substance, governments implement policies that address 
social and health-related issues of substance use. However, when a 
substance is illegal, that implies more involvement of bodies like the 
Ministry of Justice. 
For argument’s sake it is important to make a clear distinction between 
politics and policy. Politics decides which ideas the government 
believes in and policy is what a government does to support its ideas. 
This distinction helps us to understand the two basic dimensions of 
the term “integrated policy”. The integration of substances into a one-
policy document points to the political dimension. The integration of 
co-ordination refers to the policy dimension.
In everyday language, talking about drugs and alcohol policy, the term 
“policy” refers to both politics and policy. For that matter, the policy 
in place reflects the politics of that country, but when we come to do 
policy analysis it helps to distinguish policy from politics. 
2.2.  Research questions
This book is part of the second phase of a pilot study on integrated 
policy. The first phase is theoretical6 in nature and attempts in part to 
define “integrated policy” based on literature, theory and definitions 
in different countries (without limitations to specific countries). The 
second phase has an empirical character, focusing on what integrated 
policy means in different countries and how it is organised. The empir-
ical phase is limited to seven countries.7
1.  What does “integrated policy” mean in different countries? (This 
implies definition-based empirical data/ideology.)
2.  How is “integrated policy”, as defined in answer to question 1, organ-
ised? (This is operationalisation.)
The seven countries that participated in this pilot study were selected 
on the criteria of diversity (integrated/non-integrated) and their 
willingness to participate. 
5. WHO 1998a at www.euro.who.int/observatory/Glossary/TopPage?phrase=public+health 
(retrieved 11 May 2010). 
6. Reflection: research question 2 of phase 1 (What does “integrated policy” mean in dif-
ferent countries? definitions based on literature) is in fact an empirical question, not a 
theoretical one, because it looks for data on existing definitions. 
7. Germany, Ireland, Netherlands, Norway, Portugal, Switzerland and United Kingdom. 
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2.3.  Methods
The seven Pompidou Group representatives of the countries involved 
in this pilot study identified national experts on drug policy. A short 
open questionnaire containing the necessary research questions was 
sent to the national experts. The completed questionnaire formed the 
basis of a telephone interview with the expert. A list of specific issues 
that needed clarification was drafted, as well as background informa-
tion for each of the seven countries. 
All seven national experts completed the questionnaire. In some coun-
tries (Ireland, Portugal, the Netherlands) two experts completed the 
questionnaire; in Norway, Switzerland and Portugal, one questionnaire 
was completed jointly by two experts. In each country at least one 
expert was interviewed (by telephone) to provide additional infor-
mation and elaborate on some of the answers. The UK expert also 
provided comments and a written reply. 
Besides the data collected from the completed questionnaires and 
the telephone interviews, the overall findings are also based on the 
country summaries included in the Council of Europe publication 
(Muscat, 2008), and on information found on websites and national 
policy papers of the seven countries. 
2.4.  Results
The data obtained from the completed questionnaires and telephone 
interviews revealed several forms of integration in use by the partici-
pating countries. 
Integration of substances and behaviour in one policy structure 
(Norway, Germany).
Integration of co-ordinating institutions (Portugal, the Netherlands 
and Switzerland; also Ireland, in progress). 
Integration as a comprehensive needs-based approach, as opposed 
to a top-down ‘one size fits all’ approach (Portugal).
The countries that are known for having policies that are not integrated 
(the Netherlands and UK) indeed have different policy papers on each 
of the different substances (alcohol, tobacco and other substances). In 
the Netherlands the co-ordination of these single policies is done by 
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the Department of Health. In the UK, the Home Office co-ordinates 
policy on illegal drugs. With respect to alcohol, co-ordination is the 
shared responsibility of the Department of Health and Home Office. 
Tobacco policy is co-ordinated by the Health Department. In the UK 
(England) however, an Inter-Ministerial Group on Substance Misuse 
determines the priorities in tackling the harm caused by alcohol and 
drug misuse. Table 1 summarises the policies in the seven countries, 
which are explained in more detail below.
Table 1: Co-ordination of policy and rationale for non/integration of 
substance policies 
Germany Integration of alcohol policy into drugs policy was done 
to get a better grip on alcohol-related problems for 
which policy had been underdeveloped (policy neglect) 
due to a focus on illegal drugs. 
Ireland As in Germany: alcohol needs the same strong policy 
structure that is in place for illegal drugs. Tobacco policy 
remains separate.
Norway Integration for better co-ordination and also because 
illegal drugs are on the political agenda. Strong health 
orientation. 
Portugal Separate policy papers, one co-ordinating body, moving 
towards integration of illegal drugs and alcohol into 
one policy. This is in line with the paradigm shift 
that increasingly considers substance use as a health 
concern, rather than a legal concern. Tobacco policy 
remains separate.
Switzerland Separate policy papers, national co-ordination 
(FOPH), cantonal execution. The process of integra-
tion of substances into one policy is the governmental 
response to critics in civil society of the paradox of 
separate policies.
The Netherlands No integration on substances, separate policy papers. 
Satisfaction with current approach. Co-ordination is 
integrated by Ministry of Health. Well established policy 
structures on different substances.
UK Separate policy papers on alcohol, tobacco and drugs. 
Cross-cutting alcohol issues are addressed in Drugs 
Strategy. Co-ordination on overlapping issues on “project 
or programme basis”. Political responsibility: for drugs 
policy, Home Office; for alcohol policy, Health Department 
+ Home Office. Well established policies on drugs, alcohol 
and tobacco. No urge to change this approach.
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2.4.1.  Integration of substance policies and co-ordination 
Norway and Germany are the best examples of integrated policy on 
psychoactive substances and compulsive behaviour, and also in respect 
to co-ordination. Both countries have issued politically approved action 
plans.8 In Norway, alcohol and drugs were integrated into one policy 
when illegal drugs became a policy issue. The Norwegian Action Plan 
mentions compulsive gambling and the use of harmful performance-
enhancing drugs, but does not deal with tobacco smoking. In Germany, 
the focus of substance policy in the 1970s and 1980s was on illegal 
drugs and, unintentionally, policy on alcohol remained underdevel-
oped. The introduction of the German Action Plan in 2003 marked 
a turning point in national substance policy. A deliberate choice was 
made to focus on all types of addiction and the action plan said of its 
strategy that “It responds more to the concrete reality of life of those 
affected than to any ideological principles” (p. 7). The choice of one 
strategy for all reflects the notion that risky consumption patterns 
and the use of multiple substances demand an integrated approach to 
health and social consequences, rather than to substances as such. The 
German Action Plan does not seem to include gambling and gaming as 
compulsive behaviour. 
2.4.2.  In the process of integrating substance policies 
and co-ordinating them
Ireland, Portugal and Switzerland are in the process of integrating alcohol 
and drugs into one policy. In Ireland and Portugal, co-ordination issues 
form part of the rationale for integrating policies. In Ireland health experts 
would like to embed alcohol policy into the well-developed drug-policy 
structure. In both countries the alcohol industry has slowed down the 
whole process on the basis of the argument that alcohol use may take 
on negative connotations by the public if associated with drug use. In 
Portugal health experts from the alcohol platform and civil society have 
made a plea for policy on alcohol-related problems to be integrated into 
the national drugs co-ordination structure. In Switzerland the Federal 
Office for Public Health has a mandate, in concert with the most impor-
tant actors, to develop a mission statement for a coherent drug policy 
covering all types of addiction (“Challenge Addiction”, expected in June 
2010). At the same time Switzerland conducts three ongoing national 
prevention programmes (drugs, tobacco, alcohol). These programmes 
were developed independently of one another. 
8. Norwegian National Action Plan on Alcohol and Drugs; German Action Plan on Drug 
and Addiction.
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2.4.3.  No integration of substance policies
The Netherlands and the UK (at least England, Wales and Scotland) 
have separate policies for the various psychoactive substances. Both 
states have policies that focus on the social and health consequences of 
substance use, though it seems that English drugs policy puts slightly 
more emphasis on negative social consequences, through its robust 
enforcement activity. In England, delivery of the drug strategy includes 
a number of cross-cutting alcohol issues. It is hard to say why these 
countries do not have an integrated policy approach on substance use 
(or for that matter, a combined strategy on substance misuse). Their 
overarching goals are broadly the same as in other countries. Country 
experts from the UK and the Netherlands indicated that their approach 
is valued as effective.
2.4.4.  Integration as a co-ordination issue
An integrated substance policy still requires co-ordination. From this 
point of view, one has to look at collaboration between ministries and 
chains of responsibility. Countries that have legal and illegal substances 
integrated into one policy also have an integrated co-ordination 
structure in place (Norway and Germany), though in these countries 
there is a division of policy labour. In Norway, for example, the new 
alcohol legislation was developed separately from legislation on other 
substances. Nevertheless, in the event of any political problems the 
minister of health has the last say in such matters. In Germany the 
federal drugs commissioner and the drug commissioners of the Länder 
set out national and Land policy. The influence of federal policy is 
limited by the resources and political priorities of the Länder. 
In Portugal and Ireland a reporting structure has been set up to provide 
information and facilitate the co-ordination of drug policy. The efforts 
in these countries to integrate alcohol into a combined drugs and 
alcohol strategy are motivated by the need for a powerful policy struc-
ture to tackle alcohol-related problems. Switzerland is undergoing a 
similar process of integration of substances and co-ordination into 
one policy but, whatever the outcome may be, the federal govern-
ment faces similar limitations as in Germany, since it shares its polit-
ical power with the cantons. Likewise in the UK, England, Scotland, 
Northern Ireland and Wales have their own political structure, but the 
UK parliament is responsible for providing the overall drug strategy. 
In the Netherlands, policy on all substances is co-ordinated by the 
ministry of health, which drafts separate policy papers on separate 
substances. If themes involve multiple ministries, representatives from 
those ministries contribute to policy-making. 
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In all countries studied, irrespective of whether they have opted 
for a single policy for each substance or an integrated policy for all 
substances, substance-related policy is co-ordinated. Each country has 
formal or informal structures that ensure that, where issues involve 
multiple policy domains, the representatives of ministers in charge sit 
together on a programme or project basis; these are commonly referred 
to as “interministerial working groups”. In some countries (Portugal, 
Norway, Germany) formal legal structures are in place to co-ordinate 
policy and monitor ongoing activities. 
2.5.  Country summaries
2.5.1.  Germany
2.5.1.1.  Assumptions underlying an integrated approach
The Action Plan on Drugs and Addiction (2003) adopts an integrated 
view of the use of psychoactive substances. This is a major change 
compared to the National Programme on Drug Abuse Control, adopted 
in 1990. The assumptions underlying the action plan are best distilled 
from the introduction written by the minister in charge.9 She speaks of 
“new thinking” that advocates a realistic drug policy, responding more 
to the concrete reality of life of those affected than to any ideological 
principles (p. 7). 
Apparently the policy has shifted from an ideological approach to a 
pragmatic approach. The previous national programme was mainly 
one-sided and geared to illicit drugs, thus overlooking the serious 
social and health-related effects of the harmful consumption of licit 
addictive substances (p. 15). Another reason to embrace an integrated 
approach was that “the overwhelming majority of addicts in Germany 
are dependent on what are known as licit addictive substances, such as 
alcohol, tobacco or pharmaceuticals” (p. 7). Apart from the above quoted 
examples and observations, the Action Plan on Drugs and Addiction is 
in line with the development of a European drug policy: “In particular, 
the drug strategy approved by the European Council in the Action Plan 
on Drugs 2002-2004 of the European Union is of outstanding political 
significance” (p. 15). The reasons mustered for the Action Plan point to 
a conceptual shift in which addiction bridges the gap between licit and 
9. Parliamentary State Secretary at the German Federal Ministry of Health and Social 
Security and Drug Commissioner of the German Federal Government.
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illicit substances. Health and social consequences seem to be equally 
important. The other argument that supports such a policy on addic-
tion is the apparent wish to be in harmony with European policy. 
2.5.1.2.  Implementation and execution of policy
Although in Germany separate treatment structures for alcohol and 
drugs largely remained in place, inclusion of alcohol in the drug 
strategy broke the ideological separation between legal and illegal 
substances. Politicians, policy makers, health professionals and the 
general public are now more aware of the potential negative social 
and health consequences of excessive use of psychoactive substances, 
including alcohol use.
2.5.2.  United Kingdom
2.5.2.1.  Assumptions underlying the approach to psychoactive substances 
The UK consists of multiple countries, and England, Scotland, Wales 
and Northern Ireland are legally and administratively separate to 
varying degrees. This contribution mainly focuses on England. 
Scotland, Northern Ireland and Wales have developed different poli-
cies on substance use. They will be dealt with only briefly at the end 
of this summary.
At first sight, the UK has separate policies on illegal drugs, alcohol and 
tobacco. In early 2008, the government published its second ten-year 
drug strategy for 2008–18 called Drugs: protecting families and commu-
nities. The strategy focuses mainly on illicit drugs, but is comprehen-
sive and covers four broad fields: robust law enforcement; action to 
prevent harm to children, young people and families; new approaches 
to drug treatment and social re-integration; and public information 
campaigns, communications and community engagement.
The national strategy on alcohol is issued by the Department of 
Health. Tobacco policy is entirely based in the Department of Health 
and seems not to be related to public security issues. The nature of the 
departments that have issued the policy papers suggests that policy 
approaches to illicit drugs, alcohol and tobacco are different and not 
integrated on a policy level. However, at several points in the drug 
strategy, alcohol and volatile substances are explicitly mentioned 
and included, especially in the field of prevention targeting young 
people, vulnerable families and deprived communities. Prevention is 
not focused only on illegal drugs “but on all substances and the risk 
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factors that we know can lead to drug use, alcohol misuse and volatile 
substance abuse (gases, glues and solvents) as well as other problems 
later in life”. Whereas in the Drug Strategy alcohol seems to play an 
important role, in the Alcohol Strategy illegal drugs are not given the 
same sort of prominence. 
2.5.2.2.  Implementation and execution of policy
In the UK there is no single policy for all psychoactive substances. The 
delivery of the Drug Strategy is the responsibility of the Home Office. 
The Drug Strategy includes a number of cross-cutting alcohol-related 
issues and actions, mainly focused on prevention and misuse. Alcohol 
is recognised and treated as a potentially harmful substance. Also, 
in the joint action plan that accompanies the Drugs Strategy, some 
actions are explicitly related to alcohol use, for instance the implemen-
tation of some measures of the Youth Alcohol Action Plan (2008). The 
Drugs Strategy Unit leads the co-ordinated and integrated delivery 
of the Drugs Strategy and joint action plan. Overall co-ordination of 
delivery of the Drugs Strategy is ensured by a working group and a 
strategy group that bring together key departments and the agencies 
involved. Overseeing the strategy group is an Inter-Ministerial Group 
on Substance Misuse, which reviews overall progress and determines 
priorities for tackling the dangers of alcohol and drug misuse. Issues of 
tobacco smoking are not addressed in the Drugs Strategy.
For delivery of the Alcohol Strategy, a cross-government ministerial 
alcohol group has been established. The ministerial group is jointly 
chaired by ministers from the Home Office and the Department of 
Health. Issues of tobacco smoking are not addressed in the Alcohol 
Strategy.
An example of an integrated approach to psychoactive substances 
on a practical level is found in the alcohol policy paper (2007). The 
International Centre for Drug Policy developed, in collaboration with 
the 32 UK medical schools, a guidebook for teaching on alcohol, drugs 
and tobacco in the undergraduate medical curriculum. This guide-
book was commissioned and funded by the drugs policy team at the 
Department of Health (England) but with the explicit aim for the guide 
to address all substances of misuse. It was published in April 2007.
In Wales (Working Together to Reduce Harm: Substance misuse strategy 
for Wales 2008-2018) and Northern Ireland (New Strategic Direction for 
Alcohol and Drugs 2006-2011) a combined substance-misuse strategy 
has been put in place. Tobacco smoking is not addressed in these 
combined strategies. Although Scotland has produced separate policy 
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papers on drugs and alcohol, the Scottish Government has recognised 
that alcohol and drugs misuse cannot be considered in isolation.
2.5.3.  Norway
2.5.3.1.  Assumptions underlying an integrated approach
The Norwegian National Action Plan on Alcohol and Drugs has been 
implemented since 2006. As the title suggests, it deals with both 
alcohol and drugs. Tobacco is not part of the action plan; gambling 
and performance-enhancing products, such as anabolic steroids, are 
not excluded but not explicitly dealt with either.
The overall objective is to reduce the negative consequences of substance 
use for individuals and for society. The main focus is on public health, 
and both treatment and prevention are targeted in the action plan. The 
action plan will run till 2010 (by the end of 2008, 15 of 147 actions had 
been wholly or partly implemented). In the Norwegian context, inte-
grated policy refers both to the inclusion of legal and illegal substances 
in one national action plan and to the co-ordination of implementation 
and execution of actions that are listed in the action plan. 
In the foreword of the National Action Plan, the Norwegian minister 
of health and care services makes explicit that solidarity with the 
individual is a key principle of the Norwegian alcohol and drug 
policy. She says, 
Substance use problems are a matter of social inequality, social 
trends, exclusion of social misfits, and overcoming challenges at 
school and in the workplace. 
This view has contributed to the development of an extensive network 
of treatment and reintegration services for people with both alcohol 
and drug problems. The Norwegian expert stated that an integrated 
policy has been put into practice “For as long as there has been an 
illicit drug policy in Norway”, because “We believe that this leads to 
better co-ordinated prevention and treatment activities.”
2.5.3.2.  Implementation and execution of policy
The execution of the action plan involves many ministries. The joint 
actions are co-ordinated by the Ministry of Health and Care Services. 
Four times a year, inter-ministerial meetings are held where status, 
follow-up, budget matters and the need for bi-lateral co-operation 
are discussed. A wide range of permanent and ad hoc bi-lateral and 
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multi-lateral forums have been set up between different ministries 
and other governmental organisations, to ensure co-ordination of the 
different actions and/or policy areas.
2.5.4.  Switzerland
2.5.4.1.  Assumptions underlying an integrated approach
If we examine Swiss objectives on drugs, alcohol and tobacco, the 
common denominator is prevention of negative health and social 
consequences of psychoactive substance use. Switzerland has imple-
mented programmes for drugs, tobacco and alcohol, all developed 
independently of one another. 
In the past few years Switzerland has faced criticisms from civil society 
of the inconsistency of its substance policy. Efforts to strengthen the 
regulations on alcohol and tobacco consumption and at the same time 
efforts to relax the total prohibition of cannabis have been criticised. 
Swiss health policy experts observed the lack of a common under-
standing and agreement on the assumptions underlying its differenti-
ated substance policy.
In spring 2010, the Federal Office for Public Health (FOPH) is due to 
finalise a policy document (mission statement: Challenge Addiction) 
that should provoke a public and political debate on the key assump-
tions of a Swiss substance policy. The idea is to shift the focus from a 
legalistic perspective to that of health. No individual substances (legal 
or illegal) should be the key to a substance policy, but the potential 
negative health and social consequences. Such an approach would 
appear to justify an integrated health-based substance policy. 
2.5.4.2.  Implementation and execution of policy
The federal Swiss government has developed programmes on alcohol, 
tobacco and drugs, supported by co-ordination of the different sections 
within the FOPH. The development took place with the participation, 
involvement and consideration of the federal, cantonal, municipal and 
institutional levels; these programmes have a duration of five years. 
Interdepartmental working groups, led by FOPH, discuss and prepare 
substance policy. The drug section, for example, includes the federal 
social insurance organisation but also police, justice, customs and 
federal statistical organisations. In this – horizontal – working group, 
the legal and political interests of the respective ministries are taken 
into account. In addition to FOPH and its internal structures, various 
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commissions take on various topics as the need may arise. In these 
commissions federal, cantonal, community and civil society represent-
atives participate.
2.5.5.  Portugal 
2.5.5.1.  Assumptions underlying an integrated approach
In Portugal, the government body responsible for issues of drugs and 
drug addiction is the Instituto da Droga e da Toxicodependencia (IDT) 
at the Ministry of Health. The main responsibility of IDT is to promote 
the reduction of use of illicit substances (drugs) and to decrease the 
problems and addictions associated with licit and illicit substance use 
(alcohol and drugs). IDT is responsible for implementation of the policy 
on alcohol and drugs. 
Alcohol has been integrated into the scope of IDT activities since 
2007, but the formal co-ordination structure (National Co-ordinator, 
Inter-Ministerial Council and National Council) was approved only on 
28 April 2010 (Decree-Law 40/2010) and the National Plan for Harmful 
Use of Alcohol 2010-2012 was due to be approved in the inter-ministe-
rial council meeting in spring 2010. Although the execution of drugs 
and alcohol policy is situated in one government structure (IDT as the 
national co-ordinating body, supported by regional delegations), there 
are separate policy papers for alcohol and illegal drugs. 
Portugal is in the process of including alcohol and drugs in one national 
policy. The National Plan against Drugs and Drug Addictions was issued 
before alcohol was incorporated under the umbrella of IDT and will be 
updated in 2012. It will then be possible to integrate in one policy paper 
the political options for an integrated approach based on substance use 
(harm/addiction) or on addictions in general. The co-ordination support 
structure, however, has been approved by the Council of Ministers. 
Based on positive experience of the existing Drug Fight Co-ordination 
model, the Alcohol Platform, created in 2008, suggests that this model 
should be adopted to address alcohol-related problems. The law decree 
that approves integrated co-ordination also decrees that representatives 
of the alcohol industry have a seat on the National Council. 
2.5.5.2.  Implementation and execution of policy
Development of a combined alcohol and drugs policy is a process 
that takes all interests into account. Representatives of the alcohol 
industry participate in developing a new integrated policy through 
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their membership of the Alcohol Platform and they also take up their 
seat on the National Council (civil society representatives). They do 
not actively support the inclusion of alcohol in a drug strategy. This 
perspective is shared by some people working in the alcohol-treatment 
field. In order to accommodate alcohol within a combined strategy 
the wording of policy objectives, documents and projects is impor-
tant. Moreover, even the name of the institute (IDT) may be subject to 
discussion, as it is now strongly related to drugs.
In 2012, when a new strategy is supposed to be launched, it will be 
possible to learn from the two years’ experience of having a partially 
integrated approach to alcohol and drugs, and this occasion will be 
an opportunity to introduce changes that may fit better with the goal 
of improving the health and well-being of different psychoactive 
substance users and of society.
The national experts who completed the questionnaire explain that 
Portuguese drug policy is integrated also because responses are devel-
oped on the basis of the needs of citizens. In almost all Portuguese 
municipalities a needs assessment was undertaken, based on consul-
tation with local experts and institutions. The responses include, 
for example, treatment, prevention, harm reduction and dissuasion. 
Integration implies that a co-ordinated policy may offer interven-
tions according to the identified needs of citizens and communities 
(as opposed to a paternalistic, ideological or single-sided approach). 
The inventory of needs took place before alcohol was included in the 
activities of IDT. Therefore, up to now, the interventions put in place 
are mainly focused on drugs-related issues, and alcohol-related inter-
ventions are not yet as clear and strong as those for illegal drugs. 
2.5.6.  The Netherlands
2.5.6.1.  Assumptions underlying the approach to psychoactive substances
Until now problems related to drug, alcohol and tobacco use were 
basically viewed as health risks. The distinction made in the Opium 
Act of 1976 between drugs with unacceptable risks and drugs with 
less serious risks conforms to a perspective of health orientation. Over 
the years the government has drafted policy papers on various illegal 
substances. The distinction between legal and illegal substances is 
important because available policy instruments differ according to 
the legal status of a particular substance. Another reason for not inte-
grating substances into one policy is that particular substances require 
a tailored approach rather than a generalised approach. For example, 
target groups, settings, health risks and public security issues related 
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to MDMA use require a different set of interventions than, for example, 
alcohol use. In this sense, Dutch drug policy could be characterised as 
pragmatic and problem-driven. 
Although the over-arching concept in official substance policy is still 
the preservation of health, there is growing concern that substance 
use may also contribute to social risks. Notably the use of cannabis 
and alcohol is connected to dropping out from school and is a political 
concern (Brief aan TK hoofdlijnen drugsbeleid, 2009). 
Separate legislation (Tobacco Law, Alcohol Law, Opium Act) has led 
inevitably to different policy instruments that may be used in order 
to prevent substance-use problems. According to the experts, this is 
the main reason why policies are not integrated. For instance, the very 
effective instrument of taxation can be used in tobacco and alcohol 
policy, but not in illegal drug policy. However, policy on prevention 
and care is highly integrated. 
The observation that Dutch substance policy has a strong pragmatic 
approach gives rise to the assumption that an integrated approach, to 
date, is not considered as beneficial from a co-ordination point of view. 
Even if an integrated approach is formulated at the political level, says 
one of the Dutch experts, the delivery of interventions remains tailor-
made and thus to a great extent not integrated. 
2.5.6.2.  Implementation and execution of policy
The Dutch approach to substance use is not integrated because the 
great majority of the legal policy instruments are aimed at one specific 
substance (alcohol, or tobacco, or drugs). Within the policy chain of any 
one psychoactive substance, the work of governmental stakeholders is 
more or less integrated. However, national experts prefer to speak of 
co-ordinated or concerted policy. The Ministry of Health, Welfare and 
Sports officially co-ordinates policy on all psychoactive substances. 
On drug-policy issues, representatives of the four most involved minis-
tries (Health, Justice, Internal Affairs, and Youth and Family) meet once 
every two months. They meet more often when, for example, a new 
drug policy paper needs to be drafted. Much as in other countries, in 
day-to-day practice each ministry concerned is responsible for organ-
ising its role within the overall framework. For example, money laun-
dering related to illegal drug trafficking is a concern of the ministries 
of Justice and Finance. If during preparation of an intervention other 
policy domains are involved, consultation and adjustment can take 
place between or within ministries.
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2.5.7.  Ireland
2.5.7.1.  Assumptions underlying an integrated approach 
As of June 2010, Ireland has separate policies for illegal drugs and 
for alcohol. This situation may change at the end of 2010, when a 
combined national strategy on substance misuse is expected to be 
completed and approved. In 2006 a joint committee of the Houses of 
Parliament (a cross-party committee comprising members of the Seanad 
and the Dáil)10 recommended that alcohol should be included in “a 
new national substance misuse strategy”. The rationale for the recom-
mendation was based on three considerations: 1. the characteristics 
of the substance (poisonous, an intoxicant, potentially able to create 
dependence); 2. the comparatively high levels of alcohol consumption 
in Ireland and related problematic social and health consequences; and 
3. the absence of an integrated structure to tackle alcohol-related prob-
lems. The joint committee argued that including alcohol in a national 
substance-misuse strategy would provide an effective management 
structure for tackling alcohol-related problems. 
First published in 2001, Ireland’s National Drugs Strategy includes a 
reporting structure in which government departments are responsible 
for reporting on progress in implementing the drugs strategy in their 
particular area of responsibility. They report to a senior officials group, 
which reports directly to the government. The National Drugs Strategy 
also includes a strategic framework of aims, objectives and key perform-
ance indicators and related actions, and identifies the government 
departments or state agencies with responsibility for implementing 
each action. One government minister is responsible for overseeing 
implementation of the National Drugs Strategy. On the alcohol side, 
two policy reports have been issued in recent years and have validity 
from a science perspective, but a formal structure to implement the 
recommendations in these two reports has not been established. 
For at least a decade up until 2006 there had been regular and intense 
policy debates about alcohol in Ireland, but this debate “failed to 
produce an effective policy response to problems stemming from the 
consumption of alcohol.” (Joint Committee 2006, p. 26). An integrated 
approach to alcohol and drugs would be easier to achieve than the 
creation of a parallel but separate national alcohol strategy, argued the 
joint committee. 
10. Joint Committee on Arts, Sport, Tourism, Community, Rural and Community 
Affairs.
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Following the mid-term review of the National Drugs Strategy in 2005, 
a group of experts was formed in late 2006 to advise the government 
whether the drugs strategy should continue as a stand-alone strategy 
or whether it should include alcohol. Progress was slow. The group 
could not reach consensus about whether alcohol should be included 
in a national substance-misuse strategy. Public health representatives 
were in favour but representatives of the alcohol industry were not. 
Nevertheless, on 31 March 2009, following consultation on develop-
ment of a new national drugs strategy, which revealed overwhelming 
public support for including alcohol with illicit drugs in the one 
strategy, the government approved the development of a combined 
National Substance Misuse Strategy to cover both alcohol and drugs. 
The National Drugs Strategy (2009-2016), which was launched in 
September 2009, is termed an “interim strategy” pending develop-
ment of the combined strategy. A National Substance Misuse Strategy 
Steering Committee was established in late 2009 and the combined 
strategy is expected to be drafted by the end of 2010. The alcohol 
industry is represented on this steering committee.
The alcohol industry in Ireland is well organised, having come together 
to speak through one representative body. An influential economic 
power, contributing to national exports and employing a large number 
of people, the alcohol industry has successfully lobbied government 
to introduce voluntary codes of practice instead of legislation in the 
area of alcohol advertising (2005). In this respect, the alcohol industry 
is regarded as a legitimate stakeholder by government. In December 
2009, because of its concerns over competing (cheap) alcohol imports 
from Northern Ireland, the alcohol industry successfully lobbied the 
Department of Finance to reduce excise duties on alcohol. 
In summary, in Ireland the call for an integrated approach to tackling 
drug- and alcohol-related problems is rooted in two perceptions: the 
levels of alcohol consumption in Ireland and related problematic social 
and health consequences are comparatively high, and the existing drug 
policy framework is seen as a powerful tool through which alcohol 
issues could be addressed without too much difficulty. 
2.5.7.2.  Implementation and execution of policy 
Although the integrated strategy on drugs and alcohol misuse is not 
yet in place, on a day-to-day basis relevant government departments, 
including Health, Justice, Education and Finance, are involved in 
developing policies on alcohol, drugs and tobacco. As of today, with 
respect to alcohol and tobacco, no formal inter-departmental working 
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structure exists. However, the relevant departments meet as required 
on issues arising in relation to these substances. For example, the 
Department of Justice is responsible for alcohol licensing legislation 
and the Department of Health has no legislation on alcohol, but the 
two departments work closely together on the issues.
With regard to drugs issues, a formal reporting structure is in place, 
and the minister with responsibility for the National Drugs Strategy 
is provided with regular feedback. All departments concerned have 
appointed a person to report regularly to the Office of the Minister for 
Drugs; these individuals meet on a bimonthly basis. Development of 
the alcohol component of the proposed National Substance Misuse 
Strategy is a major agenda item at these meetings.
2.6.  Conclusion
In this empirical pilot project on integrated policy we have looked into 
the substance-misuse policies of seven European countries. Some of 
these conduct a fully integrated substance policy (Norway, Germany); 
they have integrated both politics and policy. Some countries are 
moving towards an integrated substance policy (Portugal, Ireland, 
Switzerland); and the Netherlands and UK do not have an integrated 
policy on psychoactive substances. 
Integrated policy, however, does not necessarily refer to the integra-
tion of substances alone. It can also refer to the integration of co- 
ordination. In Figure 1 these two dimensions are modelled in a matrix. 
The seven countries are positioned in the matrix according to their 
current state of integration of substances and co-ordination.
The matrix shows it is possible to conduct separate policies on sepa-
rate substances and at the same time have one government body co- 
ordinate these policies. The co-ordination dimension does not take into 
account the diversity in vertical co-ordination. In the UK, Switzerland 
and Germany the national government sets out legislation and guide-
lines but to a certain extent lower political structures (e.g Scotland, Wales 
and Northern Ireland in the UK, bundesländer in Germany and cantons 
in Switzerland) have certain decision-making powers of their own.
The countries that have made recent shifts towards integration 
of substances in one policy point to historical events or levers that 
provoked the new approach. One such lever was the insight that, due 
to the focus of politics and policy on illegal drugs, alcohol policy has 
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suffered from policy neglect. Integration of substances is a tool to 
integrate alcohol in the usually firm drug policy in place. It should 
be noted here that former Eastern European countries may have a 
different history in substance use and substance policy (see Muscat 
2008). Illegal drugs became available on the black market in these 
countries later than in Western countries. Although not researched in 
this pilot study, it seems likely that drug policy in the former commu-
nist countries has been integrated into an existing alcohol policy.
Figure 1. Two dimensions of integration: substances and co-ordination
The countries that do not have an integrated policy (and do not intend 
to have one) are apparently satisfied with current ideas on substances 
and the way policy is co-ordinated, though the public debate on certain 
aspects of substance policy is ongoing, as in all countries. 
2.7.  Discussion
In this section we share some notions that emerged from our reflec-
tions on the data. 
In order to understand the rationale behind (the shift to) integrated 
policy in some countries, a historical approach may be helpful. In most 
of the participating countries a clear distinction exists between legal 
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and illegal substances. International treaties (1961, 1972, 1988) regu-
late the freedom that nations have to develop national politics and 
policies regarding a range of substances. The emergence of the treaties 
could be understood in a historical political perspective. One could say 
that the years in which the last three international treaties were intro-
duced coincided with the emergence and development of drug use in 
modern welfare states. Although the development of an international 
drug policy is not driven by health concerns alone (Musto 1973, 1999), 
it is a response to a societal phenomenon. 
What goes for international treaties goes for national policy as well. 
Nations that observed the emergence of the drug phenomenon were 
confronted with related problems11 and responded with legislation 
and, to a greater or lesser extent, with policy addressing prevention, 
treatment and harm reduction. Muscat (2008) suggests that the major 
influence on drug politics and policy stems from public opinion. A 
historical approach is helpful to understand why countries at some 
point have made shifts in their approach to (certain) psychoactive 
substances. Countries that have shifted to integration of legal and 
illegal substances in one policy document were driven by develop-
ments in their society to do so. 
The emergence of the AIDS epidemic in the mid-1980s and 1990s 
forced many countries to adopt a pragmatic problem-driven approach 
rather than an ideological or legalistic approach. The AIDS epidemic 
also fuelled harm-reduction thinking in civil society. The harm-reduc-
tion approach assumes that, if abstinence is not within reach for the 
individual, the user should be helped to reduce the negative conse-
quences related to drug use. 
Muscat (2008) explains that substance-misuse policy is influenced 
by proximal factors (civil society, practice and science) and that distal 
factors influence the proximal factors. Figure 2 presents this model in 
a slightly adapted form. The dashed lines between the proximal factors 
indicate that they also influence each other. To take it further, both 
proximal and distal factors and policy are in a continuous interaction 
mode through popular and scientific media (not shown in the model). 
Figure 2 also shows Norman Zinberg’s famous model of drug, set and 
setting (Zinberg 1984), though what Zinberg indicates as setting is to 
a great extent represented by drug policy. Setting has an important 
influence on intended and unintended consequences of psychoactive 
substance use at micro, medium and macro levels.
11. In some countries prohibitionist legislation was established without the experience of 
actual drug problems, but due to international pressure (Musto, 1973, 1987, de Kort 1995).
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Muscat’s model describes the influence on politics rather than policy. 
The shape that politics takes (policy) depends not only on ideas but 
also on the view and tradition of public (health) management. Beyond 
doubt, there is a certain logic between ideas and the execution of 
ideas. If the idea is that the consumption of psychoactive substances, 
other than alcohol or tobacco, is sinful or bad it may lead to prohibi-
tion of these substances. If the dominant idea is that legal and illegal 
substances can be viewed as potentially damaging to health, a health 
approach to psychoactive substances comes into focus. Co-ordination 
of health-oriented interventions requires a different policy infrastruc-
ture from a merely prohibitionist approach.
Integrating policies on psychoactive substances and compulsive 
behaviour serves as a general orientation for policy. Political ideas 
take the form of policy, which is the link between idea and action. In 
substance-misuse policy, actions and responsibilities are co-ordinated 
as a means to an end. Co-ordination of the execution of ideas (policy) 
is not merely telling people who should do what. Co-ordination also 
involves (and assumes) stimulation of agreement on the ideas and 
underlying assumptions (= politics).
Figure 2: Models of Zinberg and Muscat integrated into one figure

















In the countries studied, several ministries shape a nation’s drugs policy, 
with the health and justice departments as the most important players. 
Co-ordination of interventions implies that the different ministries are 
58
Towards an integrated policy on psychoactive substances
consulted on issues that concern their policy domain. This could be 
realised by, for example, interdepartmental working groups. This type 
of co-ordination is common in most countries.
From a content (politics) point of view, the seven countries show 
converging ideas that emphasise the negative health and social conse-
quences of substance misuse and compulsive behaviour. From a co- 
ordination point of view (policy), countries choose different approaches 
related to tradition and constitution of government (polity). 
In the example of Germany, politicians believed for a long time that 
illicit drugs were the major problem in psychoactive substance use. 
This idea came into being as a result of public concern (moral panic?) 
about the high number of drug-related deaths (by overdose). This and 
other ideas have changed over time under the influence of science, 
practice and civil society, and the perception now is that alcohol and 
tobacco use cause a wide range of problems (see previous chapter). 
The National Action Plan on Drug and Addiction is based on this new 
perception of substance use (assumptions). However, inclusion of 
legal substances in the national co-ordination structure (federal drugs 
commissioner and drug commissioners in the Länder) is based not only 
on considerations of the content but also on co-ordination issues. An 
extensive drug-policy structure was already in place, and inclusion of 
alcohol in this structure was thought to be helpful to tackle problems 
related to alcohol use.
If we consider policy as a tool to co-ordinate the implementation of 
ideas, a policy that does not include all substances in one national docu-
ment or structure is not necessarily better or worse. Ideas are just imple-
mented in another way, each policy-responsible body emphasising its 
own profile (health, security) and taking into account the responsibilities 
of others. If the UK and the Netherlands feel that their alcohol policy is 
conducted effectively and efficiently, the need to integrate these poli-
cies is low. The examples of Germany and Ireland show that their will to 
integrate alcohol into the drug-policy structure is rooted in their dissat-
isfaction with a particular substance policy as it then stood. As far as we 
know this is not the case in the UK and the Netherlands.
To end this discussion, the concept of integrated policy (in various 
domains) is often used without clarifying what is actually integrated. 
An integrated view of health rather than a focus on single substances 
is one type of integration, often rooted in a growing acknowledgement 
that, from a health perspective, the legal distinction between alcohol, 
tobacco and other drugs is artificial. This could be seen as the political 
integration of substance policy. The policy part is closely related to 
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the political view, but from an analytical angle it is different. In public 
policy the co-ordination issue is at stake. It depends on the govern-
ment’s constitution and its tradition of how implementation of politics 
is co-ordinated. 
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3.  Overall conclusions
As stated in the empirical study, there is a notable difference between 
politics and policy. The politics of a particular political party or 
government are its beliefs and they determine the overall stance of 
the said grouping in relation to all issues in question. Policy on the 
other hand is the instrument through which their politics may be 
actualised. Thus with respect to alcohol, tobacco and other drugs, 
all psychoactive substances, their politics may be effected through 
public policy, which may be defined as the actions or inactions of 
government on a particular issue or issues.
In the first place, therefore, policy is based on the political agenda or 
politics of the government in office. This policy, it is argued in the 
first part of the overview (sections 1.0 and 1.1), needs to take into 
consideration the science that provides us with information on why 
some people use these substances and why some of them go on to 
be dependent/addicted. In turn, science also provides us with good 
information on the impact of use of these substances, whether they 
are used once only, on a few occasions and/or in regular or chronic 
use. To date, the main evidence used by governments has been that 
related to prevalence of use and statistics related to deaths as a result 
of use, because these bits of epidemiological information seem to stir 
most concern.
One may argue that science per se does not give us black-and-white 
answers to the questions posed and hence its evidence is not what 
the public seek nor what governments follow when putting policies 
in place. It needs to be appreciated that science in essence deals with 
probabilities – the notion that the theory most cited is most likely 
to account for the observations when put to the test. It is not that 
a theory is most cited because of the coverage it has received in 
the media, but more because it has undergone the scientific process, 
which involves peer review, and has now percolated to the surface 
and attracted public or political interest. There are instances where 
scientific findings come to the fore in the public arena that have not 
gone though the full scientific process, and this normally leads to 
such findings being retracted. 
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That science in essence deals with probability is a concept that is not 
ingrained in public perception; therefore problems arise when science 
is used to support policy and this fact is not acknowledged. The latest 
flu pandemic may be cited as a case in point. Governments in most 
parts of the world purchased vaccines in case the flu pandemic became 
a reality. Some now argue that this was an over-reaction, because the 
evidence was that the chances of a pandemic were below 50% – some 
would say only 10% – but the consequences of a pandemic were enor-
mous in terms of the number of deaths and a significant number inca-
pacitated by flu. The choice here was a matter of risk assessment and, 
more importantly, risk management. 
The risk of the flu pandemic was below 50% so one may argue it was 
not worth taking action or, to take it one step further, the resources 
allocated should have been proportional to the risk of occurrence – if 
we take the low figure, then 10% of resources should have sufficed. 
However, most of us insure our house against fire knowing full well 
that the chances of fire are less than 50%, yet losing one’s dwelling has 
enormous consequences. This leads most of us to insure our property 
every year while acknowledging that we are not going to get any return 
on such an investment, except for peace of mind, which may be the key 
in this instance.
Thus the link between the information provided by science and the 
consequences of inaction is a matter for the public to get to grips with 
if it wants to have discussions on such issues. Further examples of 
scientific findings related to health are the link between tobacco use 
and lung cancer or for that matter the consumption of alcohol and 
liver cirrhosis. Scientific findings with regard to the former state that 
the chances (or probability) of developing lung cancer are some eight 
times higher in chronic tobacco users than in those who do not smoke. 
Such evidence does not imply that all tobacco users will end up with 
lung cancer, but the chances are higher in this cohort. 
The public at large and politicians need to be aware what type of 
evidence science is able to provide and then acknowledge how it is to 
be used in policy formulation. A good example of late is that related 
to stem-cell research involving embryos. Following much public and 
parliamentary debate in the UK, a policy has been put in place which 
appears to acknowledge some misgivings by the latter but also the 
need for scientific research in this domain. In contrast, the issue of 
genetically modified organisms would appear to be a bad example 
of the place of science in public policy, because the debate started 
too late with ecological groups and business interests already firmly 
entrenched in their respective positions.
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The point raised here is that science needs to be better fostered among 
the general public and policy makers to ensure that all sides enter the 
debate on a more or less equal footing, with the understanding that 
science is all about probability, and policy in turn is all about ethics, 
economics and social factors, in which science is but one bit of the 
equation, though a part that needs to be better inculcated.
With this in mind, in the introduction to the empirical study (section 2.1) 
the one major common factor that seems to emerge and thus influ-
ences politics is that of health and well-being – generally meaning 
both physical and mental health. Institutions such as the Council of 
Europe and the EU prioritise it, and of course the WHO puts health 
first and monitors the health of nations. This per se should provide 
individual governments with the information required to put together 
health polices that take into account the use of alcohol, tobacco and 
other substances such as illegal drugs or the non-medical use of medi-
cations. The reason for such health policies is that the use of these 
substances has a major impact on health and therefore the ability to 
live a fully productive life, as estimated by DALY (disability-adjusted 
life years). Such substance use directly affects two of the three pillars of 
health (physical, mental and social) – and health and well-being form 
an essential support of these institutions.
Thus we need a scientific method that takes into account the harm 
done by these substances so as to better inform policy makers and the 
public at large. In the UK, Professor Nutt and colleagues published an 
article in The Lancet (2007, 369, 1047-1053) in which they attempted to 
do just that. They used three categories of harm – physical, mental and 
social – and divided each of these into three sub-categories: acute harm, 
chronic harm and intravenous harm for the physical domain; intensity 
of pleasure, psychological dependence and physical dependence for 
the mental category; and lastly intoxication, other social harms and 
healthcare costs for the social harms. 
Using the Delphi method they considered twenty substances, including 
the legal substances such as tobacco and alcohol, and produced a table 
that ranked them from the most harmful at number one to the least 
harmful at number twenty. As one would have predicted, heroin came 
in at number one followed by cocaine; surprisingly, some would say, 
alcohol came in at number five, tobacco at number nine, cannabis in 
position eleven and khat at number twenty. The main psychoactive 
substances were included, but the list is not exhaustive. However, for 
the first time we now have a ranking list that takes into account the 
harm these substances cause to physical and mental health, as well as 
social harms, using the scientific evidence at hand. It must be stated 
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that this was a first attempt and possibly, with more data, one might 
be able to do more sophisticated analysis such as principal compo-
nent analysis, which might make it possible to tease out the most 
important elements of the nine that contribute to the harm caused by 
these substances. Alternatively, using such evidence one might decide 
to give more weight to some of these factors. For example, it is the 
chronic or long-term effects of tobacco use that are the main cause of 
reduced life span and the life-threatening diseases that give rise to lost 
days as measured by DALY.
It seems that politics may now be better informed by science as regards 
health. Thus it may not be surprising that our empirical study suggests 
that, at least in the political domain, most of the countries studied have 
health as a central theme of policies on psychoactive substances. What 
appears to be different among these countries is the way in which 
the concept of health is enacted in policy. The issue of co-ordination 
seems to be the crux of the matter in opting for either an integrated or 
a single policy for each substance under the common theme of health. 
In effect this very question was raised in the introduction under the 
guise of the statement that structure sub-serves function, whether it 
be brain function or policy implementation.
On the side of politics, Chapter 2 of this book introduces two new 
aspects to the model generated by the Pompidou Group’s first foray 
into this area, From a policy on illegal drugs to a policy on psychoactive 
substances (Council of Europe). One new aspect is the suggestion that 
the three proximal factors – civil society, science and practice – are 
influenced by one another, and so form the distal components that 
make up the proximal ones. This appears to be true and it provides 
a more dynamic model, highlighting the need for science to get its 
message across to the public as well as practitioners so that such infor-
mation may be considered in policy formulation. For this to happen, 
it is imperative that scientists can communicate their findings more 
effectively, and to this end the Pompidou Group has organised summer 
workshops to encourage young scientists to communicate better. From 
the policy makers’ point of view, this is being addressed by needs ana-
lysis that in turn will provide the basis for a training initiative in the 
Pompidou Group’s next work programme – which will seek to better 
inform policy makers on the views from science. 
The second aspect newly highlighted by this empirical study is the idea 
of incorporating the Zinberg model that has a say on policy and not poli-
tics. Hence, the setting – policy, whether integrated or not – has some 
impact on the set or individual and the substance in question. Thus, 
it is argued, if a policy is prohibitionist (or not) this will have an effect, 
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intended or not, firstly on the desire to use and secondly on what type of 
substance to use. The point being made here is that the decision to use 
or not may be determined by the fact that there are legal repercussions 
(if the policy is prohibitionist) and this point has been further elaborated 
by Babor et al. in their 2010 book Drug Policy and the Public Good, 
but it has been suggested above that taking cognisance of the scientific 
evidence should be the main point for decision making and therefore 
the influencing factor on ongoing behaviour. 
On the point of policy again and the issue of co-ordination, it may 
be argued that the shift to an integrated policy on psychoactive 
substances – a shift which is gathering pace – may be a result of the 
focus on health and the structures in place in the relevant countries 
to support such a change. In those countries like the UK and the 
Netherlands where the focus for some time has been on health, the 
underlying structures have been in place to enable single policies in 
this domain to flourish. It will be interesting in the future to determine 
which of the various structures in the different countries better serves 
single policies for each of the substances or an integrated policy for all 
psychoactive substances. 
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